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 The Hedgehog (Hh) pathway is a conserved signaling network that plays a 
critical role during embryonic development as well as in the maintenance of adult 
tissues.  Inappropriate activation of Hh signaling has been linked in the development 
of several tumors, including pancreatic cancer.  In the context of pancreatic cancer, 
Hh pathway ligands secreted by the tumor cells activate this pathway in the tumor 
mesenchyme by a paracrine mechanism.  As the role of Hh signaling in the tumor 
mesenchyme is not fully understood, we initiated two strategies to understand how 
active Hh signaling promotes pancreatic carcinogenesis.  In a first approach, we used 
Hh pathway inhibitors to down-regulate paracrine Hh signaling in an orthotopic 
xenograft model of human pancreatic adenocarcinoma to test how this pathway is 
involved in tumor growth and progression.  These experiments revealed that blocking 
Hh signaling in the tumor stroma leads to a significant reduction in the ability of 
 xii 
tumor cells to form metastases, along with affecting signals that are important in 
maintaining the differentiation status of the tumor cells.  Second, we established a 
primary in vitro model of paracrine Hh signaling in pancreatic stellate cells.  Using 
bioinformatics analysis we found that paracrine Hh signaling activates an invasive 
gene signature in pancreatic stellate cells.  This was confirmed by three-dimensional 
invasion assays in vitro.  Several clinical trials for Hh pathway inhibitors, including 
here at the University of Michigan Medical Center, have been initiated for testing the 
efficacy of targeting paracrine Hh signaling in the treatment of pancreatic cancer.  
Our studies established important in vivo and in vitro models to ask important 
questions about the role of paracrine Hh signaling in pancreatic cancer progression.  
These studies add insight to how targeting this pathway may provide important 






Pancreatic cancer is the 4
th
 leading cause of cancer death in the United States 
with a 5-year survival of less than 6% [2].  The National Cancer Institute estimates 
that 43,140 Americans will be diagnosed with the disease and 36,800 will succumb to 
it in 2010 (www.seer.cancer.gov).  The age-adjusted incidence of the disease is higher 
in men vs. women (13.3 per 100,000 men vs. 10.5 per 100,000 women) and in 
African-American men vs. Caucasian men (16.7 per 100,000 men vs. 13.2 per 
100,000 men).  The risk factors for developing pancreatic cancer include advanced 
age, cigarette smoking, alcohol consumption, diabetes, obesity and a family history of 
the disease [3,4,5,6]. 
Pancreatic tumors can have a varying histological profile that includes 
adenosquamous carcinoma, colloid carcinoma, hepatoid carcinoma, medullary 
carcinoma, signet-ring cell carcinoma, undifferentiated carcinoma, and 
undifferentiated carcinoma with osteoclast-like giant cells [7].  Some of these 
histologies correspond to a poorer prognosis, for instance, adenosquamous and 
undifferentiated carcinoma, while others have better prognosis, such as colloid and 
medullary carcinoma [7].  The most common form of pancreatic cancer is infiltrating 
ductal adenocarcinoma.  Pancreatic cancer is characterized by a glandular neoplastic 
epithelium surrounded by an intense desmoplastic reaction, which in many cases, the 
 2 
cells in the stromal compartment greatly outnumbers the amount of tumor cells 
present in the tumor (Figure 1.1) [8].  The tumor cells express a variety of 
cytokeratins (cytokeratins 7, 8, 13, 18, and 19) and several serum carbohydrate 
antigens, such as carbohydrate antigen 19–9 (CA19–9) that are used as markers in the 
diagnosis and follow-up of pancreatic cancer patients [9,10,11].  Additionally, these 
tumors express several mucins; heavily glycosylated, high-molecular weight 
glycoproteins which protect the surface of epithelial tissues and have been associated 
with promoting the invasive and metastatic ability of several tumor types [12].  In 
pancreatic cancer, the aberrant expression of mucins including MUC1, MUC3, 
MUC4, and MUC5AC have been identified, with MUC4 expression correlating 
strongly with advanced pancreatic disease [10,13].      
While the cell of origin of pancreatic adenocarcinoma is still a matter of 
debate, there is general consensus on a progression model for this disease.  The most 
common precursor lesions of pancreatic cancer are known as PanINs (Pancreatic 
Intraepithelial Neoplasias) and are classified from 1A to 3 (the latter representing 
carcinoma in situ) based on defined histological characteristics [14].  Genetic 
alterations in PanIN lesions and pancreatic cancer have been the subject of numerous 
studies.  The defining mutation of human pancreatic cancer which is found in greater 
than 80-90% of pancreatic cancers is a single amino acid change in the KRAS gene, 
often in codon 12 or 13 that will generate a constitutively active form of the protein 
[15,16].  The Ras signaling pathway includes a number of GTPases that control 
signaling for many important cell functions, including proliferation, cell migration, 
adhesion, and apoptosis.   
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While the KRAS mutation is considered an important early “hit” in the 
development of pancreatic cancer, this mutation alone is not sufficient to drive the 
progression of invasive pancreatic adenocarcinoma.  Transgenic animals with a 
conditionally activated mutant KRAS
G12D
 under the control of pancreas-specific 
promoters PDX-1 or p48 results in animals that develop high grade PanIN lesions (up 
to PanIN-3) at 7 to 10 months of age, but few animals spontaneously progress to 
invasive carcinoma [17].  Further progression of the disease requires additional 
mutations or loss of tumor suppressor genes such as p53, p16
Ink4a
, BRCA2, and 
DPC4, a component of the TGFβ signaling pathway (Figure 1.2) [18,19,20]. 
The treatment options for patients diagnosed with pancreatic adenocarcinoma 
are relatively poor.  At the time of diagnosis, more than 85% of tumors have extended 
beyond the organ margins, starting with invasion into the peritoneum and local lymph 
nodes and then commonly followed by metastases to the liver [21].  Patients with 
evidence of metastatic disease and/or tumor encasement of the mesenteric vasculature 
are not considered candidates for surgical resection and undergo largely palliative 
chemotherapeutic regimens that include the nucleoside analog, gemcitabine.  Recent 
clinical trials that have utilized FOLFIRINOX, a chemotherapeutic regimen 
consisting of the drugs 5-FU (Fluorouracil), leucovorin (folic acid), irinotecan 
(topoisomerase inhibitor), and oxaliplatin extended the survival of metastatic 
adenocarcinoma patients for an additional 4 months compared to treatment with 
gemcitabine alone [22].  However, these treatments do not offer a cure, and all 
patients will eventually succumb to metastatic disease. 
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  For the minority of patients with resectable disease, the complete surgical 
resection of the adenocarcinoma represents the only option for long-term survival.  
Surgical removal of the tumor is usually performed by a Whipple procedure 
(pancreaticoduodenectomy) for tumors arising in the head of the pancreas or by distal 
pancreatectomy for tumors in the body and tail of the pancreas [23].  Following 
surgical resection, patients are treated with a chemotherapeutic regimen that often 
includes platinum-based therapy along with the nucleoside analog, gemcitabine.  
However, adjuvant chemotherapy only affords patients with an additional survival 
benefit of two months compared to surgery alone [24].   
Numerous clinical trials have been initiated to identify compounds that will 
improve patient survival that include: platinums; fluoropyrimidines; topoisomerase 
inhibitors; and various targeted agents including tipifarnib (farnesyltransferase 
inhibitor), marimastat (matrix metalloproteinase inhibitor), cetuximab (epidermal 
growth factor receptor (EGFR) inhibitor), erlotinib (tyrosine kinase inhibitor), and 
bevacizumab (anti-vascular endothelial growth factor A (VEGF-A) inhibitor) 
[25,26,27,28].  However, these trials have provided very limited survival benefit to 
pancreatic cancer patients.  The failure of these trials underscores our need to better 
understand the biology of the disease and the important pathways involved in tumor 
progression. 
The Hedgehog (Hh) pathway has emerged as one of the most widely studied 
signaling networks due to its important role in human development and disease.  In 
the development of the normal pancreas, Hh signaling is restricted; however, in the 
adult organ the pathway is important for the proper function of the insulin-producing 
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endocrine cells [29].  Several studies have identified the abnormal expression of Hh 
ligands, Sonic and Indian Hedgehog, in early PanIN lesions and in invasive 
adenocarcinoma cells [30,31].  Importantly, these ligands have been shown not to 
activate Hh signaling in pancreatic cancer cells directly, but rather to activate the 
pathway in the tumor mesenchyme via a paracrine mechanism [32].  However, we 
know very little about the Hh pathway target genes that are affected in the tumor 
mesenchyme and how these genes may be part of a feedback loop that enhances the 
progression of the tumor.  Recent work that parallels our own studies have suggested 
that currently available inhibitors of the pathway are only effective in down-
regulating the paracrine Hh signaling in the tumor mesenchyme and not Hh signaling 
in the tumor cells [33].  These studies pose some very important questions for the 
field that will be detailed in this thesis: Is active Hh signaling in the tumor 
mesenchyme required for pancreatic tumor progression?  What is the biological 
significance of Hh activation in the pancreatic mesenchyme?  What are the Hh 
pathway responsive genes in the pancreatic stroma?  Do these genes play a role in 
tumor metastasis, differentiation, or maintenance of a cancer stem cell population?  
Can targeting this pathway provide any therapeutic benefit to pancreatic cancer 
patients?  These questions are at the forefront of pancreatic tumor biology and have 
significant implications for treatment of patients with pancreatic cancer, as Hh 
pathway inhibitors are entering human clinical trials. 
In this thesis, I will describe how a clinically relevant Hh pathway inhibitor, 
HhAntag, affects primary human pancreatic tumor xenografts and how these data 
may give us clues to how patients may benefit from targeting paracrine Hh signaling 
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in pancreatic adenocarcinoma.  Additionally, I will detail an in vitro model system 
that has allowed us to test how paracrine signaling from the tumor cells affects the 
function of primary pancreatic mesenchymal cells.  Finally, I will detail experiments 
to identify the Hh responsive gene signature in pancreatic mesenchymal cells and 
describe my bioinformatics analysis approach to demonstrate how paracrine Hh 
signaling activates an invasive gene signature in these cells.  Taken together, the data 
described in this thesis will present a comprehensive analysis of the role for paracrine 
Hh signaling in the pancreatic adenocarcinoma microenvironment. 
 
HEDGEHOG SIGNALING PATHWAY 
The Hedgehog pathway plays a critical role during development and 
specification of embryonic tissues and organs.  Signaling occurs through autocrine 
and paracrine activation of cell surface receptors by peptide ligands.  In the 
mammalian system, active signaling is stimulated by three known ligands: Sonic 
hedgehog (Shh), Indian hedgehog (Ihh), and Desert hedgehog (Dhh).  As each ligand 
enters the secretory machinery, each protein is modified by addition of a palmitoyl 
group to its N-terminus and cholesterol to its C-terminus [34].   Shh is the most 
widely studied Hh pathway ligand with expression observed in the gut, nervous 
system, skin, and in limb bud [35,36].  Ihh is expressed in components of bone, along 
with the gut and pancreas, while Dhh has been found in neuronal compartments, 
testes and the pancreas [35].  Each ligand can equally activate the pathway and 
initiate expression of downstream Hh pathway target genes; however some Hh 
ligands may have greater potency of pathway activation in some cell types [37].   
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In the absence of ligand, the Hh ligand receptor Patched1 (Ptch1), which is 
located on the plasma membrane, represses the activity of the transmembrane protein 
Smoothened (Smo), through a mechanism that is still not clearly understood.  To 
further control the activation of the pathway, protein kinases in the cytoplasm, such as 
Protein Kinase A (PKA) and Glycogen Synthase Kinase 3β (GSK3β), phosphorylate 
the Gli family transcription factors.  This leads to proteosome-mediated cleavage of 
Gli into an N-terminal truncated form, which acts as a repressor of a subset of Hh 
target genes [38,39] (Figure 1.3 A).  In the mammalian system, there are three known 
Gli transcription factors, Gli1, Gli2 and Gli3.  Gli3 has been shown to demonstrate 
the role of a repressor, while Gli2 can be either an activator or repressor depending on 
the context, and Gli1 has been found to be an exclusive transcriptional activator [40]. 
Suppressor of fused (Sufu) is a conserved protein that can act as another negative 
regulator of the Hh pathway by binding to Gli transcription factors, both in the 
cytoplasm and in the nucleus, to prevent these factors from activating Hh target genes 
[41,42].  Conversely, ligand binding to Ptch1 releases the repression of Smo and a 
signaling cascade downstream of Smo leads to processing of the Gli transcription 
factors, predominantly Gli2, as an activator allows these proteins to translocate to the 
nucleus and activate the transcription of downstream target genes (Figure 1.3 B) [43]. 
It is not entirely clear how Smo leads to the activation of Gli transcription 
factors in mammalian cells.  In Drosophila, ligand binding to Patched releases a 
Hedgehog signaling complex that is attached to microtubules and membranes and is 
composed of the activating transcription factor Cubitus interruptus (Ci), the kinase 
Fused (Fu) and the kinesin-like protein Costal2 (Cos2) [44,45].  Following the release 
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of this complex, Smo is stabilized by phosphorylation at its C-terminal tail by PKA 
and Casein Kinase I (CKI), which are bound by Cos2, along with GSK3β [46].  The 
three kinases are then released and can no longer process Ci into a repressor form, 
and the full-length Ci protein is able to translocate to the nucleus to active 
downstream target genes.  In mammalian systems, Smo is found to be phosphorylated 
by the GPCR kinase GRK2 and is likely involved with other kinases in the 
stabilization of Smo in the context of Hh ligand stimulation [47,48].  The 
phosphorylation of Smo causes the receptor to traffic to the cell membrane in the 
primary cilium of the cell where the concentration of Gli transcription factors along 
with other co-factors, possibly Kif7, promotes the processing of Gli peptides into 
activating factors [49,50].     
 Recent studies have focused on the role of primary cilia in the transduction of 
Hh pathway signaling.  In the absence of ligand, Ptch receptors are located in the 
primary cilia and prevent the accumulation of Smo in the cilia; however, following 
ligand binding to Ptch, these roles are reversed and Ptch receptors are shuttled out of 
the cilia while Smo receptors are concentrated in their place [51].  Gli transcription 
factors are also known to shuttle in and out of the primary cilia.  The primary cilia 
appear to be able to form a signaling center that brings together Hh signaling 
components to coordinate the dynamic interactions among Hh signaling components 
that lead to the processing of Gli factors into either an activator or repressor form. 
  Among the best-characterized target genes associated with active Hh 
signaling are components of the pathway itself, including Gli1, Ptch1 and the Hh-
interacting protein, Hhip.  Gli1 as a target gene is specifically expressed to amplify 
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the initial Hh pathway signal and can be used as a reliable read-out for Hh pathway 
activity. Hhip, Ptch1 and the growth arrest specific protein 1, Gas1 are target genes 
that are expressed to regulate the negative feedback of Hh signaling by sequestering 
Hh ligands from stimulating Ptch receptors [52,53].   This ensures that the activity 
level of the Hh pathway is tightly regulated through a feedback mechanism.  
Depending on the cellular context, other downstream targets include cell proliferation 
and survival factors Cyclin D and Cyclin E, Bcl-2, angiogenesis related proteins 
vascular endothelial growth factor A (VEGF-A) and angiopoietins-1/2, and epithelial-
to-mesenchymal transition (EMT) related factor SNAIL [54,55,56].    
 
HEDGEHOG PATHWAY IN NORMAL PANCREATIC DEVELOPMENT 
Active Hh signaling is required during the early embryonic specification of 
the gastrointestinal tract, with the notable exception of the pancreas, where Hh 
activity is repressed by activin βB and FGF2 signals released by the notochord [57].  
This down-regulation of the Hh pathway is critical for pancreatic development as 
forced expression of Shh in the pancreatic anlage results in agenesis of the pancreas 
in mouse embryos [58].  Conversely, repression of Hh signaling in areas of the 
developing gut that normally express Hh pathway genes results in ectopic expression 
of pancreas-specific genes in the stomach and intestine [59].  While repressed during 
the early specification of cell types in the pancreatic buds, recent work using 
Patched1-LacZ transgenic mice, have identified expression of the Hh pathway 
expression via β-galactosidase (β-gal) staining as early as e10.5 in pancreatic 
epithelial cells along with some sporadic mesenchymal cell staining [29].  Patched1 
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staining increases during pancreatic development, however it later becomes restricted 
to the developing endocrine cells and pancreatic ducts.  Other studies have shown that 
additional signaling components including Ihh, Dhh, and Hhip are sporadically 
expressed around e14.5 in the developing pancreatic epithelium [60].   
In the adult pancreas, Hh pathway activity is typically very low and restricted 
to expression of Ihh, Dhh, Smo and Ptch1 in the islets housing the endocrine cells of 
the organ [60,61]; however more widespread Hh signaling can be activated under 
circumstances such as injury or disease [62].  Recent work has also demonstrated that 
Hh signaling is required for adult pancreatic function, specifically in the endocrine 
cells of the islet.  By developing a transgenic animal carrying a pancreatic epithelium 
specific promoter (Pdx-1) driving cre recombinase along with a “floxed” Smoothened 
gene the authors produced an animal with normal pancreatic morphology, but 
impaired Hh signaling in the pancreatic islets.  Specifically, these animals do not 
secrete insulin to levels comparable in wild-type animals and they developed a 
glucose intolerant phenotype [29].  These results provide another layer of our 
understanding in the role of Hh signaling in the pancreas, specifically its role in 
maintaining normal endocrine pancreatic function.  
 
HEDGEHOG PATHWAY ACTIVATION IN PANCREATIC CANCER  
Activation of the Hh pathway in primary human pancreatic cancer was first 
reported in two parallel studies [30] and [31].  The aberrant over-expression of the Hh 
pathway ligands, Sonic and Indian Hedgehog was identified in about 70% of human 
pancreatic cancer cases as well as in the majority of pancreatic cancer cell lines 
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(Figure 1.4) [31].  A similar mechanism of pathway activation has been described for 
prostate [63] and lung cancer [64], which differs from the mutation-driven activation 
of the Hh signaling pathway that has been well characterized in basal cell carcinoma 
(BCC) and medulloblastoma [65,66].   
A deeper insight on the role of Hh signaling in pancreatic cancer, and its 
relationship with other oncogenic pathways, has been obtained through the study of 
mouse models of this disease.  The most representative mouse models of pancreatic 
cancer are based on the expression of a mutated form of the KRAS gene, which 
mimics what is found in primary human cancers, specifically in the developing 
pancreatic epithelium [67,68].  In these transgenic animals, PanIN lesion 
development and progression closely resemble the human disease and interestingly 
Shh ligand is expressed in the majority of mouse PanINs even in very early 
developing lesions.  Similar activation of the Hh pathway following initiation of the 
disease using KRAS mutation has been observed in a zebrafish model of pancreatic 
cancer [69]. 
In these disease models, Hh pathway activation is downstream of KRAS 
signaling.  Some possible insight into the mechanism of Hh activation by oncogenic 
KRAS is provided by studies indicating that Shh may be a downstream target of NF-
κB [70].  NF-κB is up-regulated in response to inflammatory stimuli and cellular 
stress, conditions found in the inflamed and fibrotic environment of early-stage tumor 
lesions.  Detailed study of the Shh promoter and upstream region revealed multiple 
NF-κB binding sites that were able to activate transcriptional activity of Shh in both 
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in vitro and in vivo models [71].  This study implies that NF-κB serves as a link 
between oncogenic KRAS and Hh signaling.  
Other mouse models have more directly addressed the role of Hh signaling in 
pancreatic cancer.   Initial examination of the role of Hh signaling in the pancreas was 
examined in transgenic animals expressing Shh in the pancreatic epithelia using the 
PDX1 promoter that drives expression to the early developing pancreatic epithelium.  
These animals displayed lesions that closely resembled human PanINs and showed 
elevated expression of HER2/neu and mutated KRAS typically seen in pancreatic 
cancers [30].  However, it is not clear whether these animals would progress to a 
more advanced phenotype as ectopic expression of Shh ligand in the pancreatic 
epithelium disrupts normal pancreatic development in these animals, resulting in 
neonatal death of the mice due to pancreatic developmental defects.   
In an alternative approach, an active form of the transcription factor Gli2 was 
expressed specifically in the pancreatic epithelium starting from early pancreatic 
development [72].  Epithelial expression of the Gli2 transgene does not disrupt 
pancreas development, but it does cause formation of pancreatic tumors described as 
undifferentiated carcinomas in adult animals.  Those tumors did not progress through 
PanINs and bear little resemblance to human pancreatic ductal adenocarcinoma.  
However, simultaneous expression of active Gli2 and mutant KRAS
G12D
 resulted in 
early onset of PanINs, indicating a synergy between activation of KRAS and the Hh 
pathway in PanIN progression.  However, a recent study that mimicked canonical Hh 
signaling using transgenic animals with a constitutively active Smoothened (Rosa26-
LSL-SmoM2) that was activated via a pancreatic epithelium-specific promoter 
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(PDX1-Cre), revealed no formation of pancreatic neoplasms up to 18 months of age 
[32].  Additionally, crossing these animals with KRAS
G12D
 transgenic animals did not 
accelerate the progression of the disease nor did they observe any evidence of Hh 
signal transduction in pancreatic epithelial cells.  Laser capture of primary human 
pancreatic tumor stroma and tumor stroma from these mouse models of pancreatic 
cancer confirmed that canonical Hh signaling was restricted to the stromal 
compartment. 
These studies confirm additional data that suggests active Hh signaling is un-
coupled from the canonical mechanism in pancreatic epithelial cells compared to the 
pancreatic mesenchyme [73].  In these experiments, genetic crossing of animals with 
a Smo loss-of-function allele (Smo
F





active KRAS / p53, loss-of-function allele) background did not affect the progression 
of PanIN to adenocarcinoma, or the long term survival of the animals in the study.  In 
this model of pancreatic adenocarcinoma, downstream Hh target genes including Gli1 
are up-regulated in the pancreatic tumor cells compared to normal pancreatic 
epithelium.  However, Smo-depletion had no effect on the expression of Hh target 
genes, Gli1 and Ptch1 in micro-dissected tumor cells, suggesting that the expression 
of these targets is controlled by a Smo-independent mechanism.  Gli1 expression, 
independent of active Smo, is partially explained by TGFβ signaling, which can 
stimulate the expression of Gli1 in the absence of Hh pathway ligands.   However, 
while pancreatic tumor cells do not demonstrate canonical Hh signaling, the 
expression of down-stream target genes, including Gli1 is important for cell survival.  
Knockdown of Gli1 by siRNA in human pancreatic tumor cells resulted in increased 
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rates of apoptosis and a reduced ability to form colonies in soft agar.  Importantly, 
these studies point to divergent mechanisms for Hh signaling in the progression of 
pancreatic adenocarcinoma, in which paracrine Hh signaling activates canonical 
target genes in the tumor stroma, while Gli transcription is driven via a Smo-
independent mechanism in pancreatic tumor cells.   
        




 Paracrine Hh signaling in the tumor stroma has been identified as an important 
mechanism for Hh pathway activation in pancreatic cancer.  As pancreatic 
adenocarcinoma is characterized by a dense, desmoplastic stroma, several studies 
have taken aim to identify how Hh signaling may affect these cells.  The fibrotic 
reaction in pancreatic tumors is the result of the proliferation of supporting cell types 
including fibroblasts and stellate cells, along with the recruitment of immune cells, 
and vascular-associated cells to the growing tumor [75].  This abundance of 
mesenchymal cells in the tumor stroma supports tumor growth and progression in 
multiple ways.  These cells have been shown to secrete growth factors that aid in 
tumor proliferation by a direct feedback mechanism [76].  Additionally, these cells 
can support the growth and invasion of the tumor by secretion of extra-cellular matrix 
remodeling enzymes and expression of signaling factors that support the 
neovascularization of the tumor [77].  Additional evidence has suggested the 
desmoplastic reaction can result in the formation of a physical barrier that shields the 
tumor cells from responding to pharmacological treatments [78,79].   
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 This desmoplasia also leads to a tumor architecture that is relatively avascular 
and poorly perfused, which limits the ability of drugs to reach the tumor cells 
effectively [80].  Studies using a Smo-inhibitor, IPI-926, in a mouse model of 
pancreatic cancer have important implications for the clinical application for targeting 
the tumor stroma [80].  In this study, mouse models using mutant alleles of KRAS 
and p53 were crossed to develop transgenic animals that develop tumors with similar 
desmoplasia compared to human PDA.  In this model it was observed that the tumors 
were hypoxic, resistant to Gemcitabine, and demonstrated limited perfusion of 
compounds into the bulk tumor.  However, treatment with IPI-926 reduced the level 
of stroma, increased the perfusion of the tumors, and subsequently rendered the 
tumors more responsive to gemcitabine treatment. 
 While several studies have shown robust expression of Shh ligand in pancreatic 
tumor cells, it is unclear how cells in the surrounding microenvironment respond to 
the presence of Shh.  Recent studies have suggested that stromal cells in the 
pancreatic tissue are Hh responsive and Shh ligand signal the expansion of the 
stromal compartment (Figure 1.5) [81].  Transformed pancreatic epithelial cells that 
ectopically express Shh and transplanted orthotopically in nude mice stimulated the 
proliferation of stromal cells as evaluated by staining with the differentiated 
myofibroblast marker α-Smooth Muscle Actin (α-SMA).  The proliferation of these 
cells was modulated with treatment of the experimental animals with a blocking 
antibody (5E1) that blocks the canonical ligand-receptor interaction, resulting in the 
inhibition of downstream Hh signaling [81].  Additionally, the expression of extra-
cellular matrix (ECM) proteins collagen and fibronectin, which are characteristic of 
 16 
the desmoplastic reaction in pancreatic cancer, were significantly higher in Shh 
expressing tumors compared to tumors lacking Shh over-expression. 
 It has been hypothesized that Hh-activated stroma in pancreatic cancer may 
provide feedback signals to the cancer cells, but the specific factors in this feedback 
mechanism are still relatively unknown.  A recent microarray study of the mouse 
tumor stroma from pancreatic adenocarcinoma xenografts treated with an Hh pathway 
antagonist revealed that members of the Wnt and IGF pathways may be differentially 
regulated in response to Hh signaling [33].  Additional studies in both the intestine 
and prostate, which have similar mechanisms of paracrine Hh activation in the local 
mesenchyme, have identified pro-inflammatory and angiogenesis-related genes that 
are differentially regulated in response to Hh ligands [82,83].        
 As the tumor stroma is composed of a mixture of several different cell types, it 
is important to identify which cells are responsive to paracrine Hh signaling.  Bone 
marrow mesenchymal cells have been found to migrate to the tumor 
microenvironment and play important roles in tumor progression and angiogenesis in 
several tumor models [84,85].  Recent work has identified that these cells migrate to 
pancreatic tumors and localize to tumor endothelial cells and participate in the 
neovascularization of the tumor [86].  These cells were found to express Gli2, and 
their migration to the tumor vasculature was blocked by treating the tumor xenografts 
with the Hh pathway inhibitor, cyclopamine.  Importantly, it was found that IGF-1 in 
these cells was an important Hh target gene and that blocking this factor reduced the 
promotion of angiogenesis in both in vitro and in vivo models.  Of note, while Hh 




cells express very low levels of Gli1 and do not respond to inhibition with Hh 
pathway inhibitors [87].   
 Further evidence that paracrine Hh signaling is important for pancreatic tumor 
progression has emerged from experiments using knockouts of Hh signaling receptors 
in mesenchymal cells.  Subcutaneous implantation of Shh-expressing pancreatic 
cancer cells with mouse embryonic fibroblasts (MEFs) that have been rendered 
unresponsive to Hh signaling by knockout of the Hh signaling receptor Smoothened 
(Smo) resulted in a marked reduction in xenograft tumor growth compared to co-
implantation with wild-type MEFs [33].  These studies confirm that paracrine Hh 
signaling in the tumor stroma plays an important role in the development of 
pancreatic cancer.   
  
HEDGEHOG PATHWAY AND CANCER STEM CELLS 
 A shifting paradigm in how we view cancer is the discovery that tumors are 
comprised of a heterogeneous mixture of cells with distinct populations that have 
unique tumor-initiation capability termed cancer stem cells.  Much of the groundwork 
for identifying these cells was initiated by the application of lessons and techniques 
learned in identifying populations of normal, non-tumorigenic stem cells.  To assess 
for these tumor-initiating cells, primary tumor cells from blood-borne cancers [88] 
along with solid tumors of the breast [89], brain [90], colon [91], along with several 
other solid tumor systems, are isolated and single cell suspensions from these cancers 
were stained with various cell surface marker combinations, sorted by fluorescent 
activated cell sorting (FACS) analysis and then implanted orthotopically or 
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subcutaneously in immune compromised animals.  The resulting tumors were 
analyzed for their ability to recapitulate the histological and surface marker 
phenotype of the primary tumor as well as the ability to retain these characteristics 
following serial transplants into recipient animals to assay for self-renewal.   
 These concepts have been met with some controversy some research has 
challenged that these cancer stem cells are the result of artifacts of the assay and that 
given the proper conditions the “differentiated” cancer cell population could form 
tumors in animals or even that these tumor-initiating cells may not be as rare as we 
think [92].  Indeed, a recent study demonstrated that 1 out of 4 melanoma cells were 
capable of forming new tumors in xenograft experiments, suggesting that these 
tumorigenic cells are not a rare sub-fraction of cells in melanoma [93].  Counter to 
this is a limiting dilution analysis study of tumor cells isolated from pancreatic 
adenocarcinoma, lung cancer, and head/neck cancer which suggests that from this 
group of tumors the tumorigenic capacity is 1/2500 to 1/36,000 cells depending on 
the tumor type and individual sample [94].   While much work is still to be done to 
answer these questions in all tumor model systems, evidence from the identification 
of breast cancer stem cells in transgenic mouse models of breast cancer which bypass 
concerns about human/mouse xenograft models [95], along with data describing 
unique abilities of cancer stem cells to evade radiation [92] and chemotherapy 
treatments [96], make it clear that these cells represent a distinct cell population for 
further study in human cancers.       
 Evidence for a role of Hh signaling in cancer stem cells has come from both 
hematopoietic and solid tumor models of cancer.  Specifically, in breast cancer stem 
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cell populations, these cells were found to have 30 fold higher level of expression of 
Gli1 along with significant up-regulation of Ptch1 and Gli2 compared to non-
tumorigenic cells [97].  Additionally, in human glioma cancer stem cells, Hh pathway 
activation has been shown to be vital to the growth and survival of these cells, and 
down-regulation of Gli transcription factors either by chemical or molecular 
inhibitors leads to marked effects on cancer stem cell self-renewal and tumor 
initiating capacity [98].  
 In our own studies, we have identified a distinct population of cells within 
primary human pancreatic adenocarcinoma that are enriched in tumor-initiating cells 
and exhibit self-renewal by serial passaging in NOD/SCID animals [99].  These cells 
are marked by the expression of the cell surface markers CD44, CD24, and epithelial 
cell adhesion molecule (EpCAM) and represents a self-renewing fraction of 
tumorigenic cells which can establish tumors phenotypically identical to the primary 
patient tumor [100].  Recent limiting dilution analysis (LDA) study of tumor cells 
from multiple human pancreatic adenocarcinomas identified that the frequency of 
tumorigenic cells ranges from 1/2,500 to 1/18,000 depending on the individual patient 
tumor [94].  It is important to note that this study only evaluated three patient tumors, 
and the range of tumor-initiating cells may vary greatly depending on the phenotype 
and genotype of the individual patient tumors.  Additionally, following our initial 
publication we have identified pancreatic adenocarcinomas that either lack expression 
of CD24 or have very high levels of expression of both CD44 and CD24, which in 
some patient tumors greater than 40% of the tumor cells express these markers 
(unpublished observations).  A large scale LDA study would be ideal to compare if 
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tumor-initiating capacity correlates with the expression of CD44 and CD24 
expression, or any of the other markers that have been attributed to cancer stem cells 
in pancreatic cancer including CD133, c-Met or Aldefluor positive (ALDH
+
) cells 
[94,101].  This will shed more light on whether these markers are indeed informative 
of the cells which contain the tumorigenic activity in pancreatic adenocarcinoma.       
 The role of Hh signaling in pancreatic cancer stem cells is still very unclear.  













 cells revealed higher levels of Shh expression in the tumorigenic population 
compared to the non-tumorigenic population [99].  We can only speculate as to what 
this may mean, but it is possible that this enhanced ligand expression plays an 
important role in regulating the expression of Hh target genes in the neighboring 
tumor stroma.  Others have indirectly tested the importance of Hh signaling in 
pancreatic cancer stem cells by treatment of a metastatic cell line model of pancreatic 
cancer with the Smo inhibitor, cyclopamine [56].  These treatments did not 
significantly alter tumor size but exhibited a significant effect on preventing tumor 
metastasis and lead to a reduction of tumor cells with aldehyde dehydrogenase 
(ALDH) activity, a marker used to identify tumorigenic populations in breast cancer 
[102] and colon cancer [103].  However, these studies utilized xenografts generated 
from immortalized pancreatic cell lines and it is unclear if the cells in these lines are 
hierarchically organized and fit the cancer stem cell model.  Additionally, while 
ALDH activity may represent a tumorigenic population in some solid tumors, this 
population of cells has not been validated by in vivo implantation assays for 
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pancreatic adenocarcinoma.  Some unpublished observations in our lab suggest that 
while ALDH
+
 cells have tumorigenic potential, they do not encompass all of the 
tumorigenic cells within the tumor as we also see tumors arising from animals 
implanted with ALDH
-
 cells.   
 It is reasonable to hypothesize that Hh signaling in the tumor stroma may 
provide positive feedback signals in the form of secreted factors or changes to the 
tumor microenvironment that helps to maintain the pancreatic cancer stem cell 
population.  Down-regulating Hh signaling in either the tumor cells by targeting Gli 
transcription factors by siRNAs or in the tumor stroma by use of Hh pathway 
inhibitors will help to define the importance of Hh signaling to this cell population.  
These will be important questions to answer in the future as we develop better in vitro 
and in vivo models that allow us to construct a more comprehensive picture of the 
role of Hh pathway signaling in the tumor microenvironment. 
 
CLINICAL INHIBITORS OF THE HEDGEHOG PATHWAY 
 We have learned much about the role of Hh signaling in pancreatic tumor 
development from genetic manipulation of the Hh pathway in mouse models.  The 
efficacy of targeting this pathway in xenograft models and in patients has been tested 
by the development of several targeted inhibitors of the Hh pathway.  The discovery 
of an important Hh pathway inhibitor was made after newborn livestock were found 
with developmental defects, including cyclopia, when the female parental animals 
grazed in fields that contained corn lilies [104].  A specific compound isolated from 
these plants was named, cyclopamine, and was found to be a potent antagonist to the 
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Hh signaling receptor, Smoothened (Smo) [105].  Several screens of small-molecule 
libraries have identified more specific compounds with increased bioavailability that 
also antagonize Smo signaling, including: HhAntag, SANTs1-4, GDC-0449, and IPI-
926 [106,107,108,109].  Additionally, other molecules that target different parts of 
the Hh signaling pathway, including a blocking peptide against the Hh pathway 
ligand, Sonic Hedgehog, and small molecules that target the Gli transcription factors, 
Gli1 and Gli2, have been developed for down-regulation of Hh signaling [110,111].  
 Several of these Hh pathway inhibitors are now in Phase I and II clinical trials 
to test their efficacy in patients with a variety of tumors involving the Hh pathway 
including: basal cell carcinoma (BCC), breast cancer, gastric cancer, 
medulloblastoma, small-cell lung cancer, myeloma, ovarian, and pancreatic cancer 
[66].  Early results from clinical trials that have been published using GDC-0449 in 
patients with basal cell carcinoma have been encouraging.  In this report, 18 of 33 
patients had distant metastatic disease, and the response rate for all 33 patients was 
55% [112].  This study also demonstrated that patients were able to tolerate extended 
Hh pathway inhibition.  The median exposure to drug was 9.8 months, with side-
effects including weight-loss, fatigue, hyponatremia that did not go above grade 3 and 
in fewer than 10% of patients in the study.  Interestingly, in a separate case report of a 
patient with metastatic medulloblastoma, GDC-0449 treatment resulted in a rapid 
decrease of tumor burden; however, within several months the patient relapsed and 
developed resistance to the treatment and ultimately succumbed to the disease [113].  
These results underscore the limitations of targeting Hh signaling alone and why 
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expanding upon our knowledge of how Hh pathway is involved in tumor progression 
is important for designing therapeutic treatments for patients.    
 In contrast to treatment of tumors driven by Hh pathway mutations, it 
will be important to identify how targeting Hh signaling in tumor-stromal interactions 
will affect the progression of the disease as the dominant effect will be on the tumor 
microenvironment.  A Phase I clinical trial is currently underway at the University of 
Michigan Medical Center to test the clinical response of patients with pancreatic 
adenocarcinoma treated with the Hedgehog pathway inhibitor, GDC-0449, in 
combination with gemcitabine.  Additionally, we and others have initiated studies to 
identify the Hh responsive genes in the pancreatic tumor mesenchyme and this 
information will help us to understand how these inhibitors are affecting the 
pancreatic tumor microenvironment.  These studies will provide important data to 
determine if targeting paracrine Hh signaling may provide a therapeutic benefit for 
pancreatic cancer patients 
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FIGURES 
Figure 1.1 Pathology of Pancreatic Adenocarcinoma Progression. (A) 
Histological stain of normal human pancreas. (B) High-power magnification of a 
PanIN-2 lesion.  (C) Low-power magnification of an infiltrating pancreatic 
adenocarcinoma.  (D) Gomari’s trichrome stain of human pancreatic adenocarcinoma.  
Note the large amount of connective tissue staining (blue-green stain) compared to 






Figure 1.2 Progression Model of Pancreatic Cancer.  The most common pre-
cancerous lesions are termed pancreatic intraepithelial neoplasms (PanINs), graded 
from 1-3.  Hedgehog ligands have been detected as early as PanIN1.  Adapted from 




Figure 1.3 Diagram of Canonical Hh Pathway Activation.  (A) In the absence of 
Hh ligand, Gli transcription factors are down-regulated or processed to a repressor 
form which prevents activation of downstream target genes.  (B) Following ligand 
binding to Ptch, Smo is phosphorylated and stabilized at the cell membrane by a 
kinase complex.  Gli transcription factors are not processed to a repressor form and 


























Figure 1.4 Expression of Shh in Human Pancreatic Adenocarcinoma.  IHC image 
of normal human pancreas and a pancreatic adenocarcinoma xenograft stained for 
human Sonic Hedgehog (Shh, brown color).  Nuclei are counterstained with 
hematoxylin.  Staining is restricted to the neoplastic cells, while there is no Shh 
expression detected in the neighboring stroma. 
 
 
Pancreatic Cancer Xenograft Normal Human Pancreas 
Anti-Sonic Hedgehog 
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Figure 1.5 Paracrine Mechanism of Hedgehog Pathway Activation.  Pancreatic 
tumor cells secrete Hh ligands (Shh, Ihh) into the tumor microenvironment, which 
activates the pathway in surrounding tumor fibroblasts.  This paracrine activation, in 
turn, leads to the expression of a subset of yet uncharacterized Hh target genes that 
may play a role in fibrosis, along with neo-vascularization, recruitment of 






INHIBITION OF PARACRINE HEDGEHOG SIGNALING IN HUMAN 





Aberrant activation of the Hedgehog (Hh) pathway has been associated with 
the progression of several tumor types.  In pancreatic cancer, a paracrine mechanism 
has been identified in which pancreatic tumor cells secrete Hh ligands and activate 
the hedgehog pathway in the surrounding tumor mesenchyme.  We set out to identify 
the role of paracrine Hh signaling in pancreatic cancer biology utilizing an orthotopic 
model of human pancreatic ductal adenocarcinoma (PDA). Treatment of patient-
derived PDA xenografts grown ectopically in the pancreas of mice with HhAntag 
alone, a potent Hh pathway inhibitor and Smoothened antagonist, did not 
significantly affect primary tumor volume.  However, we observed a significant 
decrease in the number of distant metastases with HhAntag treatment.  Co-treatment 
with the nucleoside analog, gemcitabine, a chemotherapeutic agent commonly used to 
treat pancreatic cancer, enhanced these affects and also resulted in differentiation of 
the tumor cells to a mucin producing phenotype.  Finally, we observed a significant 







tumors treated with HhAntag. Re-implantation of tumor cells from both HhAntag-
treated and HhAntag/gemcitabine co-treated animals resulted in a significant decrease 
in subsequent tumor growth compared to cells implanted from either control or 
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gemcitabine only treated animals, suggesting that HhAntag treatment decreases the 
tumor-initiating capacity of cancer cells.  These results provide important insights 
into how targeting paracrine Hh signaling in pancreatic cancer may provide 
therapeutic benefits to patients. 
 
INTRODUCTION 
 Pancreatic ductal adenocarcinoma (PDA) is a devastating disease that ranks 
fourth in cancer-related death in the United States, with 5-year survival rates of less 
than 5% [115].  Most PDA patients present clinically with non-resectable, metastatic 
disease. Current therapies include the cytotoxic agent gemcitabine, but a very limited 
therapeutic effect is observed.  Even in cases where the disease is identified in its 
early stages, nearly all patients that undergo surgical resection of the tumor along 
with adjuvant chemotherapy will eventually relapse and succumb to recurrent disease 
[116,117].  Clinical trials that have evaluated the efficacy of targeting pancreatic 
adenocarcinoma with antagonists of the human epidermal growth factor receptor 
(EGFR) pathway, vascular endothelial growth factor (VEGF) pathway, insulin-like 
growth factor (IGF) pathway, and phosphoinositide 3’-kinase (PI3k)/Akt/mammalian 
target of rapamycin (mTOR) signaling have only demonstrated marginal clinical 
response in patients [27,28,118,119].  This underlines the need to develop a better 
understanding of pancreatic tumor biology and identify specific pathway targets 
which will improve clinical response. 
The Hedgehog (Hh) signaling pathway has become an important area of 
research for pancreatic cancer following initial studies demonstrating up-regulation of 
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several pathway components in human cell line models and primary samples of  
pancreatic cancer [30,31].  In normal pancreatic development, expression of Hh 
signaling ligands is blocked in the developing pancreatic bud to allow for proper 
specification of the gland [57].  In the adult organ, Hh signaling is active at low-levels 
in pancreatic β-cells and is important for the regulation of insulin secretion [61].  In 
pancreatic tumors, Hh ligands, Sonic hedgehog (Shh) and Indian hedgehog (Ihh), are 
expressed in both early precursor pancreatic intraepithelial neoplasms (PanINs) and in 
advanced adenocarcinoma [30,120].  Desert hedgehog (Dhh), a third Hh pathway 
ligand that is involved in the formation of nerve sheaths and plays a role in the 
regulation of insulin secretion of pancreatic β-cells has not been characterized in 
pancreatic cancer [61]. 
Recent studies have demonstrated that while pancreatic tumor cells express 
Hh ligands, the tumor cells are not competent to transduce canonical Hh signals [32].  
This suggests that Hh ligands secreted from the tumor cells initiate a paracrine 
mechanism in which Hh acts in the stromal compartment of the pancreatic tumor.  
Paracrine Hh signaling in the stroma creates a feedback loop in which downstream 
Hh-targets are secreted from the stroma and believed to aid in the growth and 
invasion of the tumor.  Although it is unclear which factors are involved, members of 
the Wnt and IGF pathways have been shown to be differentially regulated in the 
stroma of PDA xenografts treated with Hh pathway inhibitors [33,86].  Additionally, 
over-expression of Shh by tumor cells may contribute to the intense desmoplasia that 
is characteristic of the disease by stimulating the proliferation of pancreatic stellate 
cells [81].    
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Hh pathway inhibitors have been shown to limit the growth of human PDA in 
experimental models in vivo [30,121,122].  Recent data has suggested that targeting 
paracrine Hh signaling in a mouse model of pancreatic adenocarcinoma may improve 
the blood flow within the tumor by ablating the tumor stroma and allowing expansion 
of the vasculature, thus dramatically improving the effectiveness of cytotoxic drugs, 
such as gemcitabine, by increasing exposure to the tumor cells to the 
chemotherapeutic agent [80].  Despite these studies, it is still relatively unknown how 
targeting paracrine Hh signaling in primary human pancreatic adenocarcinoma can 
affect important aspects of tumor biology that include proliferation, metastasis and 
cancer stem cell function.  It was our aim to develop an orthotopic model of paracrine 
Hh-pathway inhibition, using primary human pancreatic adenocarcinoma xenografts 
to answer these questions. 
  
MATERIALS AND METHODS 
Treatment of Orthotopic Human PDA Xenografts 
Animals used in this study were maintained in facilities approved by the 
American Association for the Accreditation of Laboratory Animal Care in accordance 
with the current regulations and standards of the US Department of Agriculture and 
Department of Health and Human Services.  All studies were approved by the 
University Committee on Use and Care of Animals at the University of Michigan.  
Samples of human pancreatic adenocarcinomas were obtained within 30 min 
following surgical resection according to Institutional Review Board–approved 
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guidelines.  Expansion of primary human pancreatic adenocarcinoma samples using 
NOD/SCID animals have been described previously [123].   
To establish orthotopic xenografts, after administration of anesthesia, a small 
subcostal laparotomy was performed, and single cell suspensions of human PDA 
cells, transduced with a lentivirus-expressing Renilla-Luciferase, were then injected 
(5.0 x 10
5
/ 50 μl) into the distal pancreas of NOD/SCID animals.  Tumors were 
allowed to engraft for 2 weeks, following confirmation of a positive bioluminescence 
signal performed by i.p injection of luciferin and use of a Xenogen IVIS™ 200 
Imager (Caliper Life Sciences; Alameda, CA).  Animals were randomized into four 
treatment groups, seven per group, and treated for 21 days with either vehicle (0.5% 
methylcellulose (Sigma; St. Louis, MO) plus 0.2% Tween80 (Sigma), HhAntag 100 
mg/kg by oral gavage (twice daily), gemcitabine 50 mg/kg once a week, or a 
combination the HhAntag and gemcitabine regimens.  After 21 days of treatment, 
primary tumor weight was measured and metastases quantified along with harvesting 
of tissue for histological and FACS analysis. 
Drugs 
HhAntag was provided by Genentech (South San Francisco, CA)  [33].  
HhAntag was prepared as a 10 mg/ml solution in 0.5% methylcellulose (Sigma) plus 
0.2% Tween80 (Sigma) and delivered by oral gavage 10 mg/kg twice daily.  
Gemcitabine (Eli Lilly; Indianapolis, IN) was re-suspended in sterile PBS and 
injected intraperitoneally at 50 mg/kg once a week. 
RNA Extraction and Quantitative Real-Time Reverse Transcription-PCR 
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Tumor fragments (20 mg) were harvested from each treatment group, and the 
tissue was homogenized with a rotor-stator homogenizer (Polytron; Kinematica, 
Bohemia, NY) in RLT buffer (Qiagen; Valencia, CA). Total RNA was extracted 
using the RNeasy Mini kit (Qiagen).  Total RNA quality and quantity was analyzed 
using a NanoDrop (Thermo Scientific; Rockford, IL).  One microgram of total RNA 
was used to transcribe cDNA using the SuperScript® First-Strand Synthesis System 
(Invitrogen; Carlsbad, CA).  From this cDNA reaction, 2 μl of RT reaction was used 
for qPCR using POWER SYBR Mix (Applied Biosystems; Carlsbad, CA) and the 
reaction was carried out on a Roto-Gene Q Real-Time Cycler (Qiagen).   
Primers used for qPCR are as follows: mouse Gli-1 forward: GGA AGT CCT 
ATT CAC GCC TTG A, reverse:
 
CAA CCT TCT TGC TCA CAC ATG TAA G; 
mouse Ptch-1 forward: TTG TGG AAG CCA CAG AAA ACC, reverse: TGT CTG 
GAG TCC GGA TGG A; mouse GAPDH forward: AGC CTC GTC CCG TAG ACA 
AAA T, reverse:
 
CCG TGA GTG GAG TCA TAC TGG A, human Gli-1 forward: 
GTT CAC ATG CGC AGA CAC ACT, reverse: TTC GAG GCG TGA GTA TGA 
CTT C; human Ptch-1 forward: CGG CAG CCG CGA TAA G, reverse: TTA ATG 
ATG CCA TCT GCA TCC A, human GAPDH forward: CCA CAT CGC TCA GAC 
ACC AT, reverse: GCA
 
ACA ATA TCC ACT TTA CCA GAG TTA A.    
Histology 
Paraformaldehye-fixed (4%), paraffin-embedded tissue sections were stained 
with H&E in the histology lab of the University of Michigan Comprehensive Cancer 
Center Tissue Core.  For immunohistochemistry, deparaffinized and rehydrated slides 
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were subjected to antigen retrieval via autoclaving in a 10 mM citric acid buffer (pH 
6.0). Upon cooling to room temperature for 30 min, slides were blocked with 0.3% 
H2O2 for 20 min, washed in phosphate-buffered saline (PBS), and then blocked with 
1% BSA in PBS. Slides were incubated with diluted primary antibodies overnight at 
4°C. The following primary antibodies were used: rabbit anti-ki67 (1:200 dilution; 
Novocastra), Cleaved caspase 3 was detected using a rabbit anti-cleaved caspase 3 
antibody (1:100 dilution; Cell Signaling Technologies; Danvers, MA).  Slides were 
developed using the Vectastain ABC kit (Vector Labs; Burlingame, CA).  3-3′-
Diaminobenzidine tetrahydrochloride was used as a chromogen and counterstained 
with hematoxylin. 
Flow Cytometry Analysis of Cancer Stem Cell Markers 






cancer stem cell population after 
treatment with HhAntag or vehicle was carried out using FACS analysis as previously 
described [123].  Dissociated cells were counted and transferred to a 5-mL tube, 
washed twice with HBSS containing 2% heat-inactivated FBS, and re-suspended in 
HBSS with 2% FBS at concentration of 10
6
 cells/100 μL. Sandoglobin solution (1 
mg/mL) was then added to the sample at a dilution of 1:20 and the sample was 
incubated on ice for 20 min. The sample was then washed twice with HBSS/2% FBS 
and re-suspended in HBSS/2% FBS. Antibodies were added and incubated for 20 min 
on ice, and the sample was washed twice with HBSS/2% FBS. When needed, a 
secondary antibody was added by re-suspending the cells in HBSS/2%FBS followed 
by a 20-min incubation. After another washing, cells were re-suspended in HBSS/2% 
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FBS containing 4′, 6-diamidino-2-phenylindole (DAPI; 1 μg/mL final concentration). 
The antibodies used were: anti-CD44 phycoerythrin (PE) (BD Biosciences; San 
Diego, CA), anti-CD24 FITC (BD Biosciences), anti–EpCAM-allophycocyanin 
(APC) (Miltenyi Biotec; Auburn, CA), and biotinylated anti-H2K (Southern Biotech; 
Birmingham, AL) each at a dilution of 1:40.  A strepavidin-APC-Cy7 (BD 
Biosciences) was also used. In all experiments using human pancreatic cancer 
primary xenograft tissue, infiltrating mouse cells were eliminated by discarding H2K
+
 
(mouse histocompatibility class I) cells during flow cytometry. Dead cells were 
eliminated by using the viability dye DAPI. Flow cytometry was done using a MoFlo 
(Beckman Coulter; Brea, CA). Side scatter and forward scatter profiles were used to 
eliminate cell doublets. Cells were routinely sorted twice, and the cells were 
reanalyzed for purity, which typically was >98%.     
Statistical Analysis 
To compare the incidence of metastasis in the orthotopic model, we used a Fisher's 
exact test to compare treatments, whereas a Mann–Whitney test was used to calculate 
any significant difference in the weight of the primary tumors.  Fischer’s exact test 
was performed to calculate significant differences in the number of animals with 
distant metastases.  All statistics were compiled by using Prism version 5.01 
(GraphPad Software, Inc.). 
 
RESULTS 




 Paracrine Hh signaling has been detected in mouse models of pancreatic 
cancer and in human cell line xenografts [32,33].  To further define the role of Hh 
signaling in pancreatic cancer, we established xenografts from tumor fragments 
obtained from 13 patients that had undergone surgical resection for pancreatic ductal 
adenocarcinoma (Table 2.1).  In these xenotransplantation models, as the tumor 
grows in the host mouse, the human tumor stroma is quickly replaced with host 
mouse stroma [124].  To test whether paracrine Hh signaling was active in primary 
human PDA xenografts, we examined the gene expression levels of several Hh 
pathway related genes using mouse/human species specific probe sets.  Expression of 
Hh ligands, Sonic and Indian Hedgehog (Shh, Ihh), was found to be significantly up-
regulated in our PDA xenografts compared to the expression of these genes in several 
samples of normal human pancreas (Figure 2.1 A).  Additionally, using 
human/mouse specific probes, we observed a correlation between the levels of Shh 
and Ihh expression in the tumor and activation of Hh signaling, as evaluated by Gli1 
and Ptch1 expression in the mouse stroma (Figure 2.1 B).  This data supports the idea 
that paracrine Hh signaling in the tumor stroma is active in human PDA xenografts. 
 
HhAntag and Gemcitabine Treatment of Orthotopic PDA Xenografts 
 
 To test how paracrine Hh signaling contributes to pancreatic ductal 
adenocarcinoma tumor growth and progression, we established an orthotopic model 
of human PDA using low passage (≤ passage 2) cells derived from patient xenograft 
tumors.  After establishing these tumors in the pancreas of NOD/SCID animals, we 
treated the mice with HhAntag, an orally bioavailable Hh pathway inhibitor that 
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targets the Smoothened (Smo) receptor of the Hh pathway and prevent downstream 
activation of Hh target genes [33].  In parallel, we treated groups of animals with 
weekly doses of gemcitabine, a chemotherapeutic drug commonly used in the 
treatment of pancreatic cancer [24], or a combination of gemcitabine and HhAntag.   
We selected two different patient xenografts from our initial Hh pathway 
analysis for our in vivo study.  UM-PDA#1 was classified histologically as a poorly 
differentiated adenocarcinoma, expressed very high levels (40%) of cancer stem cell 
markers CD44 and CD24 [99], and subsequent follow-up with the patient revealed 
the disease had quickly progressed to Stage IV with metastasis to the liver  (Table 
2.1).  UM-PDA#2 was classified as a moderately differentiated adenocarcinoma and 
had a lower percentage of the cancer stem cell population (4%) (Table 2.1).  
Quantitative expression analysis (2
-^ΔCt
) by qRT-PCR of Sonic hedgehog for UM-
PDA#1 and UM-PDA#2 was found to be 0.026 and 0.020, respectively, which was 
just below the statistical median (0.054) for the group of xenografts analyzed in this 
study (Table 2.2).   
Treatment of both tumor xenografts with HhAntag for 21 days resulted in 
slight reductions in primary tumor volume; however, these changes did not reach 
statistical significance (Figure 2.2 A).  Treatment with gemcitabine alone did result 
in significant decreases compared to controls, with a 47% and 87% reduction in 
tumor volume for UM-PDA#1 and UM-PDA#2, respectively.  Combinatorial therapy 
with HhAntag and gemcitabine resulted in a 77% decrease for tumor UM-PDA#1 and 
an 83% decrease in UM-PDA#2, compared to control treated tumors.  The effect of 
HhAntag and gemcitabine treatment on animals with UM-PDA#1 xenografts 
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demonstrated synergistic activity, while the same treatment of animals with UM-
PDA#2 xenografts was not statistically different from treating with gemcitabine 
alone.  Animal weights remained the same as vehicle treated controls and no animals 
lost significant total body weight (>5%) which was determined by weekly weight 
measurements taken during treatment (data not shown). 
Next, we investigated the effects of Smo-inhibition on cell proliferation and 
apoptosis.  HhAntag treatment did not have a significant effect on the overall cellular 
proliferation of either UM-PDA#1 or UM-PDA#2 as evaluated by Ki67 positive cells 
(Figure 2.2 B).  Additionally, treatment with gemcitabine alone did not result in 
significant decreases in proliferation with either tumor xenograft.  We did, however, 
observe a significant decrease in the overall proliferation with co-treatment of 
HhAntag and gemcitabine in both xenografts (Figure 2.2 B).  Similar to the results 
with overall proliferation, we did not observe significant changes in the number of 
apoptotic cells in HhAntag or gemcitabine only treated xenografts (Figure 2.2 C).  
However, we did observe a significant increase in cell death in the UM-PDA#1 
animal xenografts co-treated with HhAntag and gemcitabine as evaluated by an 
increase in the staining for cleaved caspase 3 (CC3) (Figure 2.2 C).  Numbers of 
apoptotic cells in the UM-PDA#2 animal xenografts co-treated with HhAntag and 
gemcitabine were not statistically different from controls.  These results suggest that 
Smo-inhibition alone is not enough to slow the growth of the tumor by either 
reduction of mitotic signals or an increase in pro-apoptotic mechanisms.  However, 
co-treatment with HhAntag and gemcitabine was able to decrease proliferation in 
both patient xenografts and increase the amount of apoptosis in one of the xenografts 
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providing evidence that these drugs may act synergistically in reducing pancreatic 
tumor growth.        
To confirm that HhAntag treatment down-regulates the Hh pathway, we 
performed qRT-PCR from RNA extracted from bulk tumor tissue from each 
treatment group using mouse and human specific primers for Gli1 and Ptch1.  We 
observed that mouse stromal Gli1 and Ptch1 were significantly decreased compared 
to controls in both HhAntag and combination treated xenografts, while Hh target gene 
expression levels were unchanged in the infiltrating mouse stromal component in 
gemcitabine treated animals (Figure 2.2 D).  Unexpectedly, we observed increases in 
human Gli1 levels in UM-PDA#1 and human Ptch1 levels in UM-PDA#2 with 
gemcitabine and co-treatment with HhAntag (Figure 2.2 D).  It is possible that these 
treatments disrupted paracrine signals in the stroma that lead to non-canonical up-
regulation of these factors.       
 
HhAntag Treatment Induces Differentiation in PDA Xenografts  
Examination of histological sections from xenograft-derived tumors treated 
with HhAntag alone or in combination with gemcitabine revealed the appearance of 
vacuolated structures within the tumor cells.  In tumors from UM-PDA#1 animals, we 
observed these structures in both the HhAntag only and combination treated group, 
but not in the vehicle or gemcitabine-only treated tumors (Figure 2.3 A).  Trichrome 
staining, which helps to differentiate tumor cells from the connective tissue, identified 
a reduction in stromal cells in the regions surrounding the tumor cells with the 
vacuolated pattern in the tumors co-treated with HhAntag and gemcitabine.  Periodic 
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acid-Schiff (PAS) staining confirmed that the vacuolated structures contained large 
amounts of mucin (Figure 2.3 A).  In the UM-PDA#2 treated tumors, we only 
observed these structures in the combined HhAntag and gemcitabine treated animals.  
We also observed a significant change in the tumor architecture compared to control 
treated tumors with the majority of tumor cells arranged in papillary-like structures 
with large vacuolated spaces (Figure 2.3 B).  Similar to UM-PDA#1 xenografts, 
trichrome staining of UM-PDA#2 tumors from animals treated with HhAntag and 
gemcitabine treated animals revealed a reduction in the stroma surrounding the 
differentiated tumor cells.  PAS staining of sections from these HhAntag and 
gemcitabine treated tumors confirmed the expression of mucin in these structures 
(Figure 2.3 B).  To date, this change in the apparent differentiation of PDA tumors 
following inhibition of paracrine Hh signaling alone, or in combination with 
gemcitabine treatment, has not been previously described. 
  
HhAntag Treatment Decreases Metastasis in Orthotopic PDA Xenografts 
 
Pancreatic ductal adenocarcinoma is a highly metastatic disease; therefore we 
determined whether inhibition of paracrine Hh signaling was capable of suppressing 
the development of distant organ metastases in our orthotopic model.  We selected 
UM-PDA#1 for further analysis, as this tumor xenograft had demonstrated metastatic 
potential in previously performed studies in our laboratory. UM PDA#2 did not 
display metastatic potential when implanted in orthotopically in NOD/SCID mice.  
After 21 days of control, HhAntag or gemcitabine only treatment, along with co-
treatment with both drugs we sacrificed the animals from each treatment group for 
pathological analysis.  We observed in control treated animals, significant metastatic 
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spread of the disease to the peritoneal cavity, along with invasion into mesenteric 
lymph nodes and to the liver (Figure 2.4 A).  Examination of these metastatic sites 
revealed lesions histologically identical to the primary tumor (Figure 2.4 B).  In 
animals that were treated with HhAntag alone or co-treatment of HhAntag and 
gemcitabine, we did not detect metastases to the lymph nodes or peritoneum (Figure 
2.4 C).  Animals treated with gemcitabine also had significant reductions in 
metastases to the lymph nodes and peritoneum.  We observed reductions in the 
numbers of metastases to the liver with HhAntag treatment alone and in combination 
with gemcitabine, although this did not reach statistical significance (Figure 2.4 C).        
 
HhAntag Treatment Affects the Pancreatic Cancer Stem Cell Population 
 
 Previous work in our lab has identified a highly tumorigenic subpopulation of 
cells within pancreatic ductal adenocarcinoma that express CD24, CD44, and 
epithelial cell adhesion molecule (ESA) that we have termed cancer stem cells (CSC) 
due to their ability to self-renew and produce the heterogeneity of cancer cells that are 
present in the patient’s tumor [99].  We hypothesized that knockdown of paracrine Hh 
signaling in the tumor stroma may alter factors that contribute to the maintenance and 
self-renewal of this population.  To evaluate whether HhAntag or gemcitabine 
treatments affected this population of cells, we performed FACS analysis on single 
cell suspensions prepared from tumors in each treatment group.  Analysis of 







 population following any of the drug treatments compared to 
vehicle (Figure 2.5 A).  However, FACS analysis of xenograft UM-PDA#2 revealed 






 cells following HhAntag treatment alone and 
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in combination with gemcitabine, while the cancer stem cell population in the 
gemcitabine only treated animals did not change significantly from control animals 
(Figure 2.5 B).  To see if the tumorigenicity of these cells had been affected by the 









 (viable, human tumor cells) from cells dissociated 
from tumors in treatment group.  After 6 weeks, we excised the tumors from each 
group and compared their final tumor weights (Figure 2.5 C, D).  Re-implanted cells 
from HhAntag and co-treatment of HhAntag and gemcitabine resulted in tumors that 




 In this study, we tested the role of paracrine Hh signaling in the growth and 
progression of human pancreatic ductal adenocarcinoma xenografts.  Our findings are 
consistent with other studies that have shown a significant reduction in metastases to 
distant organ sites, including lymph nodes and peritoneum, following inhibition of 
paracrine Hh signaling [122,125].  We also observed a previously unreported effect of 
HhAntag to enhance the apparent differentiation of cancer cells with marked increase 
in tumor production of mucin.  In addition, the areas surrounding the differentiated 
structures in the animals co-treated with HhAntag and gemcitabine were mostly 
devoid of stroma compared to control and treatment with either drug alone.  We also 
demonstrated that HhAntag treatment can reduce the tumorigenic capacity of human 
PDA cells following re-implantation of the treated cancer cells. 
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 Our studies, along with others, have demonstrated that pancreatic tumor cells 
secrete Hh ligands, and this activates Hh signaling in the surrounding tumor 
mesenchyme [33].  However, down-regulation of paracrine Hh signaling alone in 
human PDA xenografts does not result in a significant reduction in primary tumor 
volume.  This result is consistent with the finding that Smo-inhibition in a mutant 
KRAS/p53 transgenic animal model of pancreatic cancer does not significantly affect 
primary growth of the tumor [80].  However, we observed significant reductions in 
primary tumor volume with combination treatment of HhAntag and gemcitabine in 
both patient xenografts.  The use of both drugs was synergistic in the treatment of 
UM-PDA#1, but not UM-PDA#2.  This suggests that different patient tumors respond 
differently to Hh targeted therapy, and these differences warrant further investigation 
to help identify which patients may optimally benefit from this therapy. 
We also observed that the PDA xenograft model was sensitive to gemcitabine 
treatment, raising a limitation to this model system as only 15% of patients respond to 
gemcitabine treatment [24].  Recent studies have demonstrated that a transgenic 
mouse model of human PDA, which conditionally expresses mutant KRAS and p53 
alleles in pancreatic cells, generates pancreatic adenocarcinoma that is highly 
desmoplastic and poorly perfused [80].  Cell lines made from these tumors, and re-
implanted back into immune competent animals, resulted in tumors that were well-
perfused and sensitive to gemcitabine treatment, suggesting that de novo tumor 
development rather than xenotransplantation may better approximate the human PDA 
disease response to gemcitabine.  Noticeably, in our xenograft model, the infiltrating 
mouse stroma that replaces the human stroma in the tumor appears reduced from the 
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primary patient tumor. Despite these limitations, treatment of xenotransplanted 
tumors provided important insight into the response of individual patient tumors, and 
demonstrated distinct responses to HhAntag not observed in the transgenic model of 
pancreatic cancer, such as the development of a more-mucin-producing epithelial 
component.   
Our study also suggests a previously unreported role for paracrine Hh 
signaling in maintaining the differentiation status of the tumor epithelium.  Both 
xenografts treated with a regimen of HhAntag alone or in combination with 
gemcitabine resulted in tumor regions with punctuate, vacuolated structures in the 
tumor cells that contained mucins.  Interestingly, in the case of xenograft UM-PDA#2 
co-treated with HhAntag and gemcitabine the tumor architecture was significantly 
altered to a papillary structure, with very prominent glandular differentiation.  
Typically, cell proliferation and differentiation display an inverse relationship, in that 
the most aggressive tumor malignancies are characterized by a high rate of 
proliferation and an absence of differentiation [126].   
Our results suggest that paracrine Hh signaling in the tumor stroma likely 
provides important feedback signals to the tumor cells that maintain their 
differentiation status.  Co-treatment with HhAntag and gemcitabine further enhances 
this phenotype, and suggests that the combination of these two drugs could be used to 
decrease the amount of stroma, enhance drug delivery, and induce a more 
differentiated and less aggressive tumor cell phenotype.  Interestingly, this 
differentiated phenotype has also been observed in a patient following post-treatment 
biopsies in a phase I clinical trial at the University of Michigan Medical Center using 
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GDC-0449, an Hh pathway inhibitor and Smoothened antagonist developed by 
Genentech to treat naïve patients with metastatic pancreatic cancer (Figure 2.6).  
While this clinical trial is still in the early stages, and we will need to do additional 
studies to correlate the phenotypes seen in our xenograft studies with patients in the 
clinical trial, our results may help predict how inhibition of paracrine Hh signaling 
affects primary patient tumors and demonstrate the utility of the primary pancreatic 
cancer xenograft model to predict results observed in human patients. 
The reduction in the development of metastases following inhibition of 
paracrine Hh signaling in animal models of pancreatic cancer has been reported in 
several recent studies [80,122,125].  Unique to our study was the use of non-
immortalized patient-derived adenocarcinoma cells implanted orthotopically in 
NOD/SCID animals.  It has been our experience in developing primary xenografts 
from several patient samples, that there is a range of tumor invasiveness in vivo, 
amount of infiltrating mouse stroma, the level of tumor differentiation, and the 
expression of signaling factors, including Hh pathway ligands.  By testing a range of 
patient tumors we hope to better understand what treatments might work for different 
individual tumor phenotypes.      
In our study, we utilized an invasive pancreatic ductal adenocarcinoma 
xenograft that under control treatment conditions, led to significant invasion of the 
liver, spleen, mesenteric lymph nodes, and the peritoneum.  Following treatment with 
HhAntag alone or in combination with gemcitabine, we were unable to detect 
metastases in the lymph nodes or in the peritoneum.  We also observed a reduction in 
the number of animals with metastasis to the liver in HhAntag only treated and co-
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treatment with gemcitabine, but this change was not statistically significant.  While 
we classified metastatic spread as evidence of any metastases to distant organs, 
HhAntag and co-treatment with gemcitabine clearly had a significant impact in 
limiting the tumor burden to the liver and peritoneum.  Experiments are on-going to 
track the level of metastases by using luciferase-tagged tumor cells and whole organ 
imaging.  This will help to establish quantitative measurement of changes in tumor 
burden following treatment.  Additionally, it will be important to assess if inhibition 
of paracrine Hh signaling is able to inhibit the growth of established metastases, as 
many patients present clinically with late-stage, metastatic disease. 
The role of cancer stem cells is also a focused area of study for solid tumor 







 expression in one of our two treated xenografts following 
HhAntag treatment alone and in combination with gemcitabine compared to control.  
Our in vivo results with HhAntag suggest that this drug does not affect the tumor cells 
directly, therefore any change in the tumorigenic cell population is likely to be due to 
the differential expression of factors from the mesenchyme that maintain the cancer 
stem cell niche.  Studies are underway to perform limiting dilution analysis (LDA) 
from tumor cells following each treatment regimen.  This is a more robust 
measurement of tumor initiating capacity [93] and will clarify whether Smo-
inhibition in the stroma is effective in disrupting the maintenance of the cancer stem 
cell population.      
Targeting paracrine Hh signaling in the pancreatic tumor mesenchyme may 
provide an important therapeutic target for pancreatic adenocarcinoma patients.  
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There are still many questions to be answered about how paracrine Hh signaling 
affects the biology of the tumor mesenchyme and what Hh responsive genes may be 
differentially regulated that lead to the changes in tumor biology observed in our 
studies.  These studies add to our understanding of how Hh signaling may be working 
in the pancreatic tumor microenvironment and may open up new strategies for 
treatment regimens for pancreatic cancer.  
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FIGURES 
Figure 2.1 Paracrine Hh Signaling in Human PDA Xenografts.  (A) Quantitative 
RT–PCR profiling of SHH and IHH mRNA in a panel of samples from normal human 
pancreas and low-passage (≤ 2) human PDA xenografts (normal, n=6, PDA, n=13).  
Gene expression normalized to species-specific GAPDH levels.  (B) Correlation 
between stromal-derived Gli1 and Ptch1 mRNA levels versus tumor-derived Hh 









































































































































































) hIHH vs. mPtch1




































Figure 2.2 HhAntag Treatment Targets Hh Signaling in the Tumor Stroma. (A) 
Final tumor weights (g) of Tumor UM-PDA#1 and UM-PDA#2 following treatment 
(n = 6 in each group, * denotes p-value < 0.05.  (B) IHC staining for Ki67 revealed a 
decrease in proliferation in HhAntag + Gemcitabine treated tumors for both patient 
tumors tested.  (C)  IHC staining for Caspase-3 revealed an increase in apoptosis in 
HhAntag+Gemcitabine treated tumors in UM-PDA#1 but not UM-PDA#2.  (D) qRT-
PCR analysis of each tumor following treatment using mouse/human specific Gli1 
and Ptch1 primers.  Gene expression was evaluated from two separate animals from 
each treatment group and run in triplicate.  V= vehicle, G= gemcitabine, H= 











































































































































































































































































































Figure 2.3 Evidence of Differentiation for Tumors UM-PDA#1 and #2 following 
HhAntag and Gemcitabine Treatment.  (A, C) Trichrome stain of tumor UM-
PDA#1 and UM-PDA#2 treatment groups.  Note the cytoplasmic vesicles and 
intracytoplasmic lumens found in the groups treated with both 
HhAntag+Gemcitabine.  (B, D) Periodic acid-Schiff (PAS) staining of tumor UM-
PDA#1 and UM-PDA#2 treatment groups.  Robust PAS staining for both tumor sets 























Figure 2.4 HhAntag Treatment Decreases Incidence of Distant Metastases.  (A) 
UM-PDA#1 orthotopic xenografts following 21 days of treatment.  Black arrow 
denotes the primary tumor site. (B)  H&E sections from metastatic lesions from the 
control treated xenografts (i) Tumor implant in the muscle wall of the diaphragm, (ii) 
tumor implant superficial to the liver (iii) tumor lesion in the lymph nodes adjacent to 
the small intestine, (iv) tumor lesion in the spleen. (C) Graphical representation of the 
number of mice with metastasis to different organ sites. Statistical comparisons were 
made from each treatment group compared to controls (n = 7 each, *denotes p-value 







































































































































* p-value < 0.05
Fisher's exact test
n= 7 per group
C)
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 Cells Following HhAntag Treatment.  
(A, B) FACS analysis of UM-PDA#1 and UM-PDA#2 xenografts following 
treatment.  Analysis was performed in triplicate from three individually treated 
animals (*denotes p-value < 0.05).  (C) Tumors derived from subcutaneous 
implantation of UM-PDA#2 cells from each treatment group. C=control, H=HhAntag 
only, G=Gemcitabine only, H+G=HhAntag + Gemcitabine combination (n = 3).  (D)  






































































































































Figure 2.6 Histological Analysis of Patient PDA Biopsy Before and After 
treatment with GDC-0449.  H&E sections of patient tumor biopsies prior and post 
treatment with GDC-0449.  Arrows highlight the vacuolated structures observed in 
the tumor cells post treatment (20 x magnifications). 
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 59 
Table 2.1 Origin, stage, and pathology of human pancreatic ductal 


























Table 2.2 Quantitative expression (qRT-PCR) of Hh pathway genes and cancer 






PARACRINE HEDGEHOG SIGNALING ACTIVATES CELL MOTILITY 




The Hedgehog (Hh) signaling pathway plays an important role in the 
development and function of the pancreas.  Several studies have demonstrated 
aberrant Hh signaling in the progression of pancreatic cancer.  Active Hh signaling in 
pancreatic cancer occurs through a paracrine mechanism in which pancreatic tumor 
cells secrete Hh ligands that activate the pathway in the surrounding stromal cells.  
The biological role of Hh signaling in the tumor stroma is unclear.  To identify the Hh 
responsive genes which may be activated in the pancreatic tumor mesenchyme, we 
performed transcriptional profiling on a primary, immortalized mouse pancreatic 
stellate cell line stimulated with recombinant Sonic hedgehog (Shh) ligand.  We 
identified 206 genes that were differentially regulated by Shh in these cells.  
Bioinformatic analysis of the Shh-responsive gene data set revealed a strong 
correlation with genes that increased the motility of mesenchymal cells in 
extracellular matrix.  This was confirmed by 2D and 3D invasion assays that 
demonstrated that paracrine Hh signaling increases the invasion of pancreatic stellate 
cells in type I collagen.  These results confirm that paracrine Hh signaling enhances 
the invasiveness of pancreatic stellate cells and down-regulation of this pathway may 




 The aberrant activation of Hedgehog (Hh) signaling has been characterized in 
pancreatic cancer in several studies [30,31].  Active Hh signaling in pancreatic cancer 
occurs through a paracrine mechanism in which tumor cells secrete Hh ligands, Sonic 
and Indian hedgehog (Shh and Ihh, respectively) which activate Hh pathway target 
genes in the tumor mesenchyme [32,33].  It is still unclear what biological effect 
paracrine Hh signaling imparts on the tumor mesenchyme.  However, ectopic 
expression of Shh by normal pancreatic epithelial cells has been shown to stimulate a 
desmoplastic reaction in the pancreas [81].  This expansion of stromal cells and 
extensive production of extracellular matrix components is a feature that defines 
pancreatic cancer, and appears to play a major role in the resistance of tumor cells to 
chemotherapeutic treatments and in mediating the invasiveness of pancreatic tumor 
cells [79,127]. 
 The pancreatic tumor stroma is comprised of several different components 
including stellate cells, endothelial cells, nerve cells, and immune cells such as 
macrophages, lymphocytes, dendritic cells, along with the extracellular matrix.  
Pancreatic stellate cells (PSCs) have become the main focus of studies involving 
pancreatic tumor-stromal interactions due to their critical role in the desmoplastic 
response [76].  In the normal pancreas, these cells envelop the acinar structures of the 
exocrine pancreas and remain quiescent with vacuoles that contain large vitamin-A 
deposits.  However, these cells can become activated by growth factors and cytokines 
(PDGF, IL-1, TNF-α, TGF-β, activin A) or in response to pancreatic injury or disease 
[128].  Activated PSCs lose the vitamin-A droplets, proliferate rapidly, and transition 
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to a myofibroblast-like phenotype with increased secretion of extracellular matrix 
components, including type I collagen, laminin, and fibronectin [129]. 
 Several studies have demonstrated that canonical Hh signaling in pancreatic 
adenocarcinoma is confined to the stromal compartment [32,33].  Additionally, 
stromal cells which are negative for platelet endothelial cell adhesion molecule 
(PECAM-1 or CD31), which include pancreatic stellate cells, are responsive to 
inhibitors of the Hh pathway, while CD31
+
 vascular cells do not show reduced levels 
of Hh pathway target genes in pancreatic cancer xenografts treated with an Hh 
pathway inhibitor (unpublished observations).  This suggests that pancreatic stellate 
cells are the main target of Hh ligands in the pancreatic tumor microenvironment.  
Paracrine Hh signaling in pancreatic cancer creates a positive feedback loop in 
which Hh-regulated factors are differentially expressed to promote the growth and 
progression of the pancreatic tumor cells.  These factors are likely to include mitotic 
and angiogenesis-related factors, extracellular matrix remodeling enzymes, and anti-
apoptotic proteins.  Only a small number of factors induced by paracrine Hh signaling 
in the tumor stroma have been characterized.  Bone marrow derived mesenchymal 
cells which home to the pancreatic tumor microenvironment in an Hh-regulated 
mechanism expresses Angiopoietin-1 (Ang-1) and Insulin-like growth factor-1 (IGF-
1), which supports the neovascularization of the tumor [86].  We set out to identify 
the Hh responsive gene signature in pancreatic stellate cells and identify how these 
target genes may impact pancreatic tumor biology.  
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MATERIALS AND METHODS 
Isolation and Cell Culture of Primary Pancreatic Fibroblasts 
 
Primary pancreatic fibroblasts were obtained by treating either CD-1 (Charles River; 
Wilmington, MA) mice or Immortomouse® animals (Charles River) with caerulein, 
50μg/kg every hour for 6 hours three times a week, to induce chronic pancreatitis.  
Following treatment, the fibrotic pancreata were excised and minced with a sterile 
razor blade in Media 199.  The tissue fragments were digested with 200U/ml of 
Collagenase IV (Worthington; Lakewood, NJ) for 30 min to 1 hr.  Tissue digests were 
washed several times with serum media and filtered through a 40 μm nylon mesh (BD 
Biosciences).  Wild-type cells were cultured in DMEM 10% FBS media at 37°C/5% 
CO2.  Immortomouse-derived cells were cultured in 33°C/5% CO2 with the addition 
of 10 U of mouse interferon gamma (R&D Systems; Minneapolis, MN).   
 
Cell Culture for Array and Gene Validation 
Prior to stimulation with Shh, primary and immortalized fibroblasts were incubated in 
DMEM low-serum (0.5% FBS) overnight.  Cells were treated 24 hrs with a range of 
recombinant mouse Shh (R&D systems) at 100-1000ng/ml reconstituted in sterile 
PBS.  For experiments using 5E1, a Shh blocking antibody (Iowa Hybridoma Bank), 
was added to the cultures at 1.0µg/ml at the same time as recombinant Shh.  Total 
RNA from control and treated cells was prepared for Illumina array analysis by using 
the Illumina® TotalPrep™ RNA Amplification Kit (Ambion; Foster City, CA) 
according to manufacturer’s instructions.  Samples were checked for purity and 
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normalized for the Illumina MouseRef-8 v2.0 BeadChip by the University of 
Michigan Sequencing Core.      
 
Gene Expression Analysis of Target Genes 
Following treatment, cells were trypsinized and pelleted using serum containing 
media.  Cells lysis was performed with buffer RLT (Qiagen) containing 2-
mercaptoethanol (Sigma-Aldrich).  Cell lysates were collected and homogenized with 
QiaShredder spin columns (Qiagen). For RNA extraction from tumor samples, the 
tissue was homogenized with a rotor-stator homogenizer (Polytron). Total RNA was 
extracted using the RNeasy Mini kit (Qiagen) according to the standard protocol 
provided by the manufacturer with on-column DNAase digestion.  
Total RNA quality and quantity was analyzed using a NanoDrop spectrophotometer 
(Thermo Scientific).  One microgram of Total RNA was used to transcribe cDNA 
using the SuperScript® First-Strand Synthesis System (Invitrogen).  From this cDNA 
reaction, 2 µl of RT reaction was used for qPCR using POWER SYBR Mix (Applied 
Biosystems) and the reaction was carried out on a DNA Engine Opticon Real-Time 
Cycler (MJ Research).  Primers used for qPCR are as follows: mouse Gli-1 forward: 
GGA AGT CCT ATT CAC GCC TTG A, reverse:
 
CAA CCT TCT TGC TCA CAC 
ATG TAA G; mouse Ptch-1 forward: TTG TGG AAG CCA CAG AAA ACC, 
reverse: TGT CTG GAG TCC GGA TGG A; mouse GAPDH forward: AGC CTC 
GTC CCG TAG ACA AAA T, reverse:
 
CCG TGA GTG GAG TCA TAC TGG A; 
mouse TGFß2 forward: TCG ACA TGG ATC AGT TTA TGC G, reverse: CCC 
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TGG TAC TGT TGT AGA TGG A; mouse JAM2 forward: GTG CCC ACT TCT 
GTT ATG ACT G, reverse: TTC CCT AGC AAA CTT GTG CCA; mouse SFRP2 
forward: CGT GGG CTC TTC CTC TTC G, reverse: ATG TTC TGG TAC TCG 
ATG CCG; mouse FGF9 forward: ATG GCT CCC TTA GGT GAA GTT,  reverse: 
TCA TTT AGC AAC ACC GGA CTG;  mouse ANGPT4 forward: AGC AGC AAC 
TGA CGG AGT TT, reverse: CTC TGC ACA GTC CTG GAA CA; mouse Tiam1 
forward: CCT CAC TGG GAA AGT GGA AA, reverse: TCT TCT GCT TGG AAC 
CGT CT; mouse MMP13 forward: AGT TGA CAG GCT CCG AGA AA, reverse: 
GGC ACT CCA CAT CTT GGT TT; mouse IL-6, forward TAG TCC TTC CTA 
CCC CAA TTT CC, reverse: TTG GTC CTT AGC CAC TCC TTC; mouse VEGFA 
forward: GCA CAT AGA GAG AAT GAG CTT CC, reverse: CTC CGC TCT GAA 
CAA GGC T; mouse GDF10 forward: CAG GAC ATG GTC GCT ATC CAC, 
reverse: ACA GGC TTT TGG TCG ATC ATT TC; mouse Wnt-2 forward: CTC 
GGT GGA ATC TGG CTC TG, reverse: CAC ATT GTC ACA CAT CAC CCT. 
 
Microarray Data Analysis 
 
Transcriptional profiling was performed on Illumina MouseRef-8 v2.0 
BeadChips (San Diego, CA) according to the manufacturer directions.  All 
microarray data were analyzed in the statistical software R (v 2.10.1) with associated 
packages from the Bioconductor Suite for molecular biology.  The “lumi” package 
was used for quality control and normalization of the chips, including background 
adjustment, variance stabilization and quantile normalization.  Following 
normalization, empirical Bayes estimation of moderated t- and F-statistics was 
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computed to test for differential expression.  Because of the relatively small number 
of samples, an unadjusted p-value of less than 0.05 was used to determine statistical 
significance.   
Differentially regulated genes were further analyzed using Ingenuity Pathway 
Analysis (IPA; Ingenuity Systems, Mountain View, CA; http://www.ingenuity.com). 
IPA is a Java based program used to interpret the differentially expressed genes in 
terms of an interaction network and identify predominant canonical pathways.  
Canonical pathways analysis identified the pathways from the Ingenuity Pathways 
Analysis library of canonical pathways that were most significant to the data set. 
Molecules from the data set that met the statistically significant cutoff of an adjusted 
p-value <0.05 and were associated with a canonical pathway in Ingenuity’s 
Knowledge Base were considered for the analysis.  
 
Collagen Invasion Assays 
To analyze cell invasion, 20,000 pancreatic stellate cells were embedded in 20 μl of 
type I collagen gel (2.0 mg/ml, BD Biosciences).  After gelling, the plug was 
embedded in a cell-free, 300 μl collagen gel (2.0 mg/ml) cultured within a 24-well 
plate. After allowing the surrounding collagen to gel (1 h at 37°C), invasion was 
stimulated with DMEM 10% FBS or DMEM 10% FBS media conditioned for 24 hrs 
from L3.6pl cells, a human pancreatic cancer cell line .  HhAntag was reconstituted in 
DMSO and replaced in the culture every 2 days.  3D invasion was evaluated after 5 
days in culture.  Invasion distance from the inner collagen plug into the outer collagen 
gel was quantified.  This distance was calculated as the tip of the leading front of 
 68 
stellate cells in 5 high power fields.  Imaging was obtained using a Nikon Instruments 
Eclipse Ti-U Microscope and processed using Nikon NIS-Elements software. 
 
RESULTS 
Primary culture of Mouse Pancreatic Stellate Cells (MPSCs) 
 
 Pancreatic stellate cells are specialized pancreatic support cells that have been 
identified as a major source of the desmoplasia in chronic pancreatitis and in 
pancreatic cancer [76,130].  To determine the biological role of paracrine Hh 
signaling in the pancreatic mesenchyme, we developed cultures of primary mouse 
pancreatic stellate cells (MPSCs) from both normal CD-1 mice (designated wild-type) 
and from Immortomice, the latter in order to establish a primary, immortal cell line.  
Cells isolated from an Immortomouse express a temperature-sensitive mutant of the 
simian virus-40 large T-antigen (tsTAg) and allows for conditional immortalization of 
primary cells [131].  These cells were isolated by culturing fibrotic pancreatic tissue 
fragments from animals treated chronically with caerulein, a cholecystokinin (CCK) 
analog which induces pancreatitis and activation of pancreatic stellate cells [78,132]. 
The outgrowths from these tissue fragments yielded spindle-like cells that are 
characteristic of pancreatic stellate cells.  Immunohistochemical staining of both 
MPSC lines confirmed the expression of stellate cell markers: α-smooth muscle actin 
(α-SMA) and vimentin (Figure 3.1 A).  Flow cytometric analysis (FACS) was used 
to ensure that the stellate cell lines were free of cells expressing vascular, 
hematopoietic, or epithelial markers.  MPSCs were less than 0.5% positive for both 
CD31 and CD45 and negative for expression of the ductal epithelial marker CD133 
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[133] (Figure 3.1 B).  Studies of MPSC cultures treated with recombinant mouse 
Sonic hedgehog ligand showed that downstream Hh pathway target genes Gli1, Gli2, 
Ptch1, and Ptch2 were up-regulated in a dose-dependent manner following Shh 
stimulation, as evaluated by qRT-PCR analysis (Figure 3.1 C). 
 
Transcriptional Profiling of Shh-Regulated Genes in MPSCs 
 
 To identify Shh-responsive genes in pancreatic stellate cell lines, we 
performed microarray analysis using RNA isolated from both wild-type and 
Immortomouse-derived pancreatic MPSCs cultured for 24 hrs in the presence or 
absence of recombinant Sonic hedgehog (Shh).  Isolated mRNA from 4 independent 
cultures of both wild-type and immortomouse-derived cells were biotin-labeled and 
hybridized to Illumina MouseRef-8 v2.0 BeadChips.  In both the wild-type pancreatic 
MPSC line and those derived from the Immortomouse, hierarchical clustering 
dendrograms showed a distinct pattern of gene expression in cells treated with 
recombinant Shh ligand compared with control cells (Figure 3.2 A). 
 To investigate the level of overlap between the statistically significant genes 
that were changed between wild-type and Immortomouse cells treated with 
recombinant Shh we used the R statistical software to compute an adjusted p-value of 
(p < 0.05), used as a cut-off for detecting significant difference in expression levels.  
In general, a narrow range of fold difference between the up/down Shh-regulated 
genes were observed compared to control.  We found that for the wild-type MPSC 
data set this range was 2.48 to -1.69 fold change and for the Immortomouse MPSC 
data set the range was 2.40 to -1.98 fold change.  We chose to investigate genes with 
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≥ 1.2 fold-changes with an adjusted p-value of < 0.05 for further analysis.  We 
identified 340 genes differentially expressed in the wild-type MPSC Shh treated cells 
and 206 genes differentially expressed in the Immortomouse, Shh treated cells with 
an overlap of 51 genes between the two lines (Figure 3.2 B). 
 
Bioinformatics Analysis of Hh Target Genes in MPSCs  
To simplify our analysis of Hedgehog pathway target genes in subsequent 
experiments, we utilized the data set from the Immortomouse-derived MPSCs treated 
with Shh.  We selected this set because the Immortomouse-derived MPSCs can be 
manipulated easily in vitro for co-culture with tumor cells or knockdown studies used 
for functional validation of target genes, and these cells are easily transfectable using 
standard techniques.  Additionally, it was our experience that the wild-type (normal) 
pancreatic stellate cell line would senesce in vitro after 5 passages.  Therefore, using 
the immortomouse-derived pancreatic stellate cells gave us the greatest flexibility in 
testing the role of Hh signaling in this cell type.  In the immortomouse Shh-regulated 
gene set, 125 genes were found to be up-regulated and 81 genes were found to be 
down-regulated (Figure 3.3 A, Table 3.1).   
Next, we compared our data set against two existing transcriptional profiles of 
Shh-treated mesenchyme in the intestine and prostate [82,83].  We performed this 
analysis to learn what genes and pathways are consistent with Hh activation in 
mesenchymal cells and what Hh-regulated genes may be specific to the pancreatic 
tumor microenvironment.  Meta-analysis of all three data sets was performed by 
using Ingenuity Pathway Analysis (IPA), a bioinformatics program designed to 
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identify differentially expressed genes in terms of an interaction network and identify 
predominant canonical pathways.  Among the top functional pathways consistent 
with all three Shh-responsive gene data sets were: cellular growth and proliferation, 
cell movement, cell cycle, cell death and immune cell tracking (Figure 3.3 B).  
Individual genes that overlapped between the pancreatic and intestinal data set 
include insulin-like growth factor-1 (IGF-1), growth differentiation factor 10 
(GDF10), homeobox protein Nkx2-3 and leukemia inhibitory factor (LIF).  Genes in 
overlap between our pancreatic data set and the prostate data set were identified as 
angiopoientin-4 (ANG-4), T-cell lymphoma invasion and metastasis 1 (TIAM1), 
hairy and enhancer of split 1 (HES1), and Peptidyl-prolyl cis-trans isomerase 
(FKBP1A).  Two genes, 11β-hydroxysteroid dehydrogenase type 1 (HSD11B1) and 
Sodium-and chloride-dependent taurine transporter (SLC6A6) were differentially 
regulated in all three data sets.  Additionally, we identified some factors that had not 
been shown to be Hh-related genes and were found only in the pancreatic stellate cell 
data set.  These genes included Wnt2, TGFβ2, R-spondin1, and Fgf9.  Our results 
suggest that there may be some overlap in the Hh-regulated genes in organ-specific 
mesenchyme, but there are subsets of Hh responsive genes that are specific to each 
stromal environment. 
 
Shh-regulated Expression of Hedgehog Pathway Target Genes in MPSCs 
 
 Analysis of Shh-regulated target genes in MPSCs revealed altered regulation 
of genes related to secretory functions, cell movement, and angiogenesis pathways.  
These results are consistent with the hypothesis that paracrine Hh signaling in these 
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cells supports tumor growth by altering the microenvironment.  To further validate 
these pathways, we assessed mRNA expression of representative genes identified in 
the microarray data set.  We selected nine mRNAs that were up-regulated and three 
that were down-regulated for further analysis.  The nine up-regulated genes we 
selected for validation were: Fgf9, Gdf10, Angpt4, Wnt2, Tgfβ2, Tiam1, IL6, VegfA, 
and Gli1.  The three down-regulated genes we selected for analysis were: Sfrp2, 
Jam2, and Mmp13.  In addition, as there is some speculation that commercially 
available recombinant Shh products may be contaminated with endotoxins that can 
affect expression of chemokines [134], we also assessed the specificity of the Shh-
induced gene response by culturing MPSCs in 500 ng/ml of recombinant Shh with or 
without addition of 1.0 µg/ml of the Shh blocking antibody, 5E1 [135].  Of the twelve 
genes evaluated by qRT-PCR, ten out of the twelve genes exhibited significant Shh 
regulated expression consistent with our microarray data (Figure 3.4).   
To determine if the genes identified in our Shh regulated gene profile were 
specific to pancreatic mesenchymal cells or general to Shh regulated gene expression 
in other mesenchymal cell types we performed the same gene expression analysis in 
primary mouse embryonic fibroblasts (MEFs).  We found that only five out of the 
twelve genes analyzed exhibited significant Shh regulated gene expression (Figure 
3.5).  This suggests that there is a subset of Hh pathway responsive genes, including 
Fgf9, Tgfβ2, VegfA, IL6 and Sfrp2, that may be pancreatic specific. 
 




 We identified several Shh-responsive genes in MPSCs that have been 
implicated in cell motility.  To test whether paracrine Hh signaling affects cell 
motility, we examined how MPSCs responded to Hh pathway stimulation or 
inhibition in 2-dimensional (2D) and 3-dimensional (3D) invasion assays.  For 2D 
invasion, MPSCs were seeded in the upper-well of a Boyden chamber (8 µm pores) 
and overlaid with a thin-layer of Matrigel.  Increasing amounts of recombinant Shh 
ligand was added to the lower well of the chamber and the number of invading cells 
that had transversed to the other side of the membrane were counted after 24 hrs.  
Increasing amounts of recombinant Shh added to the lower chamber resulted in 
corresponding increases in the amount of invading MPSCs through Matrigel (Figure 
3.6 A). 
 To assess how inhibition of paracrine Hh signaling affects the ability of 
MPSCs to invade in 3D extra-cellular matrix, we imbedded MPSCs in type I collagen 
plugs surrounded by a field of cell-free type I collagen.  Invasion was stimulated by 
either standard DMEM 10% serum media, conditional media from L3.6pl cells (a 
high Shh expressing pancreatic cancer cell line [33]), or conditioned media with 
increasing doses of HhAntag, a Smoothened inhibitor and Hh pathway antagonist.  
We observed a significant increase in the invasion of MPSCs following addition of 
the L3.6pl conditioned media compared to the standard media. Following addition of 
HhAntag to conditioned media, we observed a decrease in invasion in a dose-
dependent manner (Figure 3.6 B). 
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DISCUSSION  
 The tumor mesenchyme has long been implicated in playing an important role 
in tumor angiogenesis, metastasis, and overall growth and proliferation of cancer 
cells.  Work in our lab and others has demonstrated that Hh signaling is activated in 
the pancreatic tumor stroma via a paracrine mechanism in which tumor cells secrete 
Hh ligands and activate the downstream Hh target genes [33].  However, very little 
was known about what downstream genes and biological changes may be induced in 
the tumor mesenchyme by paracrine Hh signaling.  These studies are the first 
documentation of an Hh responsive gene signature in pancreatic mesenchymal cells, 
and the role of Hh signaling in stimulating the motility of these cells in extracellular 
matrix. 
 The lack of definitive cell-surface markers and early senescence of primary 
cultures prevents the direct isolation and long-term culture of pancreatic stellate cells 
from the normal pancreas.   By using a pancreatitis-induced method to activate 
pancreatic stellate cells from Immortomouse animals, we were able to derive a 
permanent cell line to manipulate for long-term in vitro and in vivo experiments.  
These cells express established markers of pancreatic stellate cells, which include α-
smooth muscle actin and vimentin [129] and are responsive to Sonic hedgehog 
ligand.   
The time point selected for microarray analysis of our pancreatic stellate cell 
lines stimulated with Hh ligand was based on previously published studies 
characterizing the kinetics of Ptch1 and Gli1 induction in Shh-treated prostate and 
intestinal mesenchymal cells [82,83,136].  Our preliminary experiments suggested 
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that 24 hrs after Shh stimulation was an optimal time point to measure a strong 
transcriptional response of both primary and secondary Hh-responsive genes.  
Quantitative expression analysis of Hh target genes, Gli1 and Patched1 (Ptch1), 
which are indicative of active Hh signaling [43] were significantly up-regulated in 
MPSCs following stimulation with Sonic hedgehog.   
Several previous studies have used microarrays to investigate the target genes 
of Shh signaling in mesenchymal cell types.  Shh-stimulation of C3H/10T1/2 cells, an 
immortalized mouse embryonic fibroblast cell line, identified 11 induced genes 
(including IGF2) and 4 repressed genes (including Sfrp-1 and Sfrp-2) [137].  Recent 
studies with Shh-stimulation of organ specific mesenchymal cells from the prostate 
and intestine have also been profiled by microarray analysis [82,83].  In comparison 
to these studies, we identified several genes in our data set that were previously 
identified as potential Hh target genes in mesenchymal cells. These include Gdf10, 
Nkx2-3, Ang-4, Tiam1, Hes1, Sfrp-2, IGF1 and IGF2.  Several of these genes have 
demonstrated important functions in pancreatic cancer and other malignancies.  IGF-1 
and Ang-2 have been shown to be up-regulated by Sonic hedgehog in bone marrow 
derived mesenchymal cells and these factors are involved in promoting the 
neovascularization of growing pancreatic tumors [86].  Additionally, aberrant 
regulation of Tiam1 in breast cancer associated fibroblasts has been shown to increase 
the invasiveness of breast cancer cells [138].   
Our studies also identified several genes that had not been previously 
identified as Hh targets.  These potential target genes included Wnt2, TGFβ2, R-
spondin1, and Fgf9.  The activation of pancreatic stellate cells from their normal 
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quiescent state to a highly proliferative state is mediated in part by TGFß signaling 
[139].  It is possible that paracrine Hh signals from the tumor help to perpetuate this 
phenotype in pancreatic stellate cells as we observed several TGFß signaling genes 
that were up-regulated with Shh-stimulation in pancreatic stellate cells.  While there 
has not been a role established for Wnt signaling in pancreatic mesenchyme, the Wnt 
pathway is up-regulated in pancreatic cancer and micro-dissection studies of tumor 
stroma from patients with pancreatic adenocarcinoma has identified the up-regulation 
of Wnt5a and down-regulation of Sfrp-1 [140,141].  Recent studies have suggested a 
role for Wnt to enhance proliferation in the epithelium and stroma of chemically 
induced bladder cancer in mice [142].  In this work, sonic hedgehog expression in 
basal cells of the bladder increases upon injury and elicits increased stromal 
expression of Wnt protein signals, including Wnt-2 expression, which in turn 
stimulates the proliferation of both urothelial and stromal cells.  This type of feedback 
mechanism may also be at work in the pancreatic tumor microenvironment.    
 Inhibition of paracrine Hh signaling in mouse models of pancreatic cancer and 
in cell line xenograft studies have demonstrated a reduction in distant metastases 
without dramatic changes in primary tumor volume [80,122].  This suggests that a 
primary role of paracrine Hh signaling in pancreatic tumor stroma is to mediate the 
invasion and extravasation of tumor cells.  Therefore, we used Ingenuity Pathways 
Analysis (IPA) to determine whether Hh-responsive genes in mesenchymal cells 
derived from organs with known paracrine Hh signaling mechanisms correlated with 
an invasive gene signature.  IPA meta-analysis confirmed that paracrine Hh signaling 
in MPSCs, along with data sets in prostate and intestinal mesenchyme, induces the 
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expression of genes that correspond with cell motility, inflammation, and mitotic 
activity.  Genes that were in overlap between the pancreatic and intestinal data set 
include insulin-like growth factor-1 (IGF1), growth differentiation factor 10 
(GDF10), homeobox protein Nkx2-3 and leukemia inhibitory factor (LIF).  
Expression of Nkx2-3 in gut mesenchyme has been linked to the specification and 
proliferation of the intestinal epithelium [143].  In overlap with the prostate data set 
we identified angiopoientin-4 (ANG-4), T-cell lymphoma invasion and metastasis 1 
(TIAM1), hairy and enhancer of split 1 (HES1), and Peptidyl-prolyl cis-trans 
isomerase (FKBP1A).  Two genes, 11β-hydroxysteroid dehydrogenase type 1 
(HSD11B1) and Sodium-and chloride-dependent taurine transporter (SLC6A6) were 
differentially regulated in all three data sets, although these genes have not been 
linked to tumor invasion. 
In order for pancreatic tumor cells to invade into the surrounding tissues, the 
cells have to overcome several physical barriers.  These barriers include degradation 
of the epithelial basement membrane, navigation of the interstitial matrix, along with 
neovascularization of the growing tumor and extravasation of tumor cells out of the 
vascular network [144].  Many of these processes are normally controlled by 
mesenchymal cells during the development of the organ and during tissue repair 
following injury [75]. When we directly examined 12 genes related to these 
functional pathways, 10 out of 12 showed specific regulation by Hh ligand which was 
reversed by treatment with 5E1 blocking peptide that inhibited downstream Hh 
pathway activation.  Interestingly, three of the genes that we analyzed including 
Wnt2, Gdf10, and IL6 were identified as differentially regulated in a microarray study 
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of tumor stroma from animals with pancreatic adenocarcinoma xenografts treated 
with a Hh pathway inhibitor [33].  Independent validation of these genes by a 
reciprocal transcriptional profiling study, suggests that these genes are indeed Hh 
target genes in the pancreatic tumor mesenchyme. 
 While we identified genes that are induced by paracrine Hh signaling, there is 
little known about how activation of this pathway affects the biological function of 
pancreatic stellate cells or cancer cells.  Recent studies using an organotypic model of 
tumor invasion has suggested that tumor cells rely on mesenchymal cells to carve 
tracks in the interstitial matrix in order to invade into the surrounding tissues [145].  
We observed that MPSCs stimulated with sonic hedgehog increased their 
transmigration through Matrigel, a pseudo-model of epithelial basement membrane.  
To test how paracrine Hh signaling affects the ability of MPSCs to navigate the 
interstitial matrix we utilized a 3D invasion assay in type I collagen.  Conditioned 
media from an Hh ligand-expressing pancreatic cancer cell line was able to increase 
the invasiveness of MPSCs in type I collagen, but this was inhibited in a dose 
response with Smo-inhibition.  These results suggest that paracrine Hh signaling in 
MPSCs plays an important role in the motility of these cells through the extracellular 
matrix.       
In summary, we have developed a primary mouse pancreatic stellate cell line 
for use in validating Hedgehog target genes in vitro, and have compiled the first data 
set describing the Hedgehog responsive genes in pancreatic stellate cells.  These 
studies have provided insight into how paracrine Hh signaling in the tumor 
mesenchyme increases the 3D migration of these cells and in turn we hypothesize that 
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this may lead to increased invasion of pancreatic tumor cells.  Future studies will be 
aimed at elucidating the functional role of these Hedgehog responsive genes and how 
they are involved in the pancreatic tumor microenvironment.  This information may 
help us to learn how Hedgehog pathway inhibitors may be working in the pancreatic 
tumor and provide insight into how we may target this pathway to improve patient 
responses to treatment.   
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Figure 3.1 Generation of Mouse Pancreatic Stellate Cell Lines.  (A) 
Representative bright-field and immunofluorescence staining of MPSCs for α-SMA 
and vimentin. MPSCs maintained their stellate-like or spindle shape through 
passaging (original magnification: ×20). (B) FACS analysis of MPSCs for CD31, 
CD45, and CD133.  (C)  Shh-stimulated dose response of downstream Hh pathway 
















Figure 3.2 Transcriptional Profiling of Shh-Regulated Target Genes in Mouse 
Pancreatic Stellate Cells (MPSCs).  (A) Hierarchical clustering of MPSC data sets 
from wild-type (WT) and immortomouse-derived (Imm) treated with recombinant 
Shh.  The R software package was used to cluster and annotate the normalized array 
data. (B) Venn diagram and table of Shh-regulated genes in overlap between the wild-
type (normal) and the immortomouse-derived MPSCs.  While 51 genes were found in 
overlap, only 42 of these genes were differentially changing in the same positive or 






Figure 3.3 Pathway Analysis of Shh-regulated Target Genes in MPSCs.   
(A) Heat-map of the top 50 up and down regulated Shh-regulated target genes in 
immortomouse-derived MPSCs.  (B) Ingenuity Pathways Analysis (IPA) of 
conserved functional pathways associated with Shh-regulated target genes in MPSCs 









Figure 3.4 Shh-regulated Expression of Hedgehog Target Genes in MPSCs.  
Specific target genes related to mitotic or invasive activity were selected for further 
analysis.  Gene expression was analyzed by qRT-PCR from MPSCs treated with 
either Shh alone or in combination with the Shh blocking antibody, 5E1 for 24hrs (n 





































































































































































































































































































































































Figure 3.5 Shh-regulated Expression of Hedgehog Target Genes in Mouse 
Embryonic Fibroblasts (MEFs).  Specific target genes related to mitotic or invasive 
activity were selected for further analysis.  Gene expression was analyzed by qRT-
PCR from MPSCs treated with either Shh alone or in combination with the Shh 




































































































































































































































































































































































Figure 3.6 Paracrine Hh Signaling Regulates 2D and 3D invasion of MPSCs in 
Extracellular Matrix.  (A) 2D Matrigel transmigration assay.  MPSCs seed in the 
upper well of a Boyden chamber (8um pores) and increasing amounts of recombinant 
Shh added to the lower chamber.  Number of invading cells counted in 5 random 
high-power fields (n = 3; **, p < 0.01; *, p < 0.05). (B) 3D collagen invasion assay.  
MPSCs seeded in a droplet of type I collagen (2mg/ml) surrounded by a field of cell 
free collagen.  Invasion induced with standard media, conditioned media (CM) from 
L3.6pl cells, or CM with increasing doses of HhAntag (n = 3; *, p < 0.05, # < 0.05 
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Table 3.1 Genes Differentially Regulated by Shh-treatment in Immortomouse 
derived MPSCs.  Table generated for genes with a statistical p-value < 0.05 and a 











     
KRT18 Mus musculus keratin 18 (Krt18), mRNA.   2.206558 
LMCD1 





Mus musculus protein tyrosine phosphatase, receptor-type, F 




Mus musculus golgi autoantigen, golgin subfamily a, 2 
(Golga2), transcript variant 1, mRNA. 
  
2.042706 
WFDC1 Mus musculus WAP four-disulfide core domain 1, mRNA   1.959638 
TGFB3 




COL4A1 Mus musculus procollagen, type IV, alpha 1 (Col4a1), mRNA.   1.83121 
TST 
Mus musculus thiosulfate sulfurtransferase, mitochondrial (Tst), 
nuclear gene encoding mitochondrial protein, mRNA. 
  
1.588525 
KRT8 Mus musculus keratin 8 (Krt8), mRNA.   1.579524 
FGF9 Mus musculus fibroblast growth factor 9   1.573808 
MID1IP1 
Mus musculus Mid1 interacting protein 1 (gastrulation specific 
G12-like (zebrafish)) (Mid1ip1), mRNA. 
  
1.551006 
FADS2 Mus musculus fatty acid desaturase 2, mRNA   1.531375 
GDF10 Mus musculus growth differentiation factor 10 (Gdf10), mRNA.   1.517269 
SMTNL2 Mus musculus smoothelin-like 2 (Smtnl2), mRNA.   1.512132 
COL4A2 Mus musculus collagen, type IV, alpha 2 (Col4a2), mRNA.   1.508298 
TGM2 




GAS6 Mus musculus growth arrest specific 6 (Gas6), mRNA.   1.482343 
BOK Mus musculus BCL2-related ovarian killer protein   1.47937 
ANGPT4 Mus musculus angiopoietin 4 (Angpt4), mRNA.   1.472825 











     
(Wnt2), mRNA. 
CP Mus musculus ceruloplasmin (Cp), transcript variant 2, mRNA.   1.457289 
CYP2S1 
Mus musculus cytochrome P450, family 2, subfamily s, 
polypeptide 1 (Cyp2s1), mRNA. 
  
1.447383 
COL6A1 Mus musculus procollagen, type VI, alpha 1 (Col6a1), mRNA.   1.440276 
KRT7 Mus musculus keratin 7 (Krt7), mRNA.   1.428984 
RSPO1 










Mus musculus ubiquitin specific peptidase 2 (Usp2), transcript 
variant 2, mRNA. 
  
1.426266 
ARL6 Mus musculus ADP-ribosylation factor-like 6 (Arl6), mRNA.   1.426228 
CTSA Mus musculus cathepsin A (Ctsa), transcript variant 2, mRNA.   1.417241 
HIST1H2AD Mus musculus histone cluster 1, H2ad (Hist1h2ad), mRNA.   1.404944 
HIST1H2AK Mus musculus histone cluster 1, H2ak (Hist1h2ak), mRNA.   1.404306 
DIO3 Mus musculus deiodinase, iodothyronine type III   1.401211 
TNFRSF21 
Mus musculus tumor necrosis factor receptor superfamily, 
member 21 (Tnfrsf21), mRNA. 
  
1.400688 
COL6A2 Mus musculus procollagen, type VI, alpha 2 (Col6a2), mRNA.   1.395217 
TNFRSF22 
Mus musculus tumor necrosis factor receptor superfamily, 









Mus musculus solute carrier family 6 (neurotransmitter 




Mus musculus hydroxysteroid 11-beta dehydrogenase 1 



















     
(nucleolar) (Gnl2), mRNA. 
PLTP Mus musculus phospholipid transfer protein (Pltp), mRNA.   1.356291 
FBLIM1 Mus musculus filamin binding LIM protein 1 (Fblim1), mRNA.   1.352369 
TIAM1 




NNAT Mus musculus neuronatin (Nnat), transcript variant 1, mRNA.   1.344158 
TSPAN33 Mus musculus tetraspanin 33 (Tspan33), mRNA.   1.338362 
WWC1 





Mus musculus pleckstrin homology domain containing, family 
A member 7 (Plekha7), mRNA. 
  
1.331558 
PMP22 Mus musculus peripheral myelin protein (Pmp22), mRNA.   1.32949 
ZFP521 
Mus musculus zinc finger protein 521 (Zfp521), transcript 
variant 2, mRNA. 
  
1.328459 
CDH3 Mus musculus cadherin 3 (Cdh3), transcript variant 1, mRNA.   1.324222 
BLMH Mus musculus bleomycin hydrolase (Blmh), mRNA.   1.321113 
CLTB Mus musculus clathrin, light polypeptide (Lcb) (Cltb), mRNA.   1.32065 
RAP2A Mus musculus RAS related protein 2a (Rap2a), mRNA.   1.314896 
ST6GAL1 









CYGB Mus musculus cytoglobin (Cygb), mRNA.   1.300345 
CCND1 Mus musculus cyclind1, mRNA   1.297539 
NUAK2 





Mus musculus growth arrest and DNA-damage-inducible 45 


















     
OLFML3 Mus musculus olfactomedin-like 3 (Olfml3), mRNA.   1.29014 
PLEKHO2 
Mus musculus pleckstrin homology domain containing, family 
O member 2 (Plekho2), mRNA. 
  
1.287191 
DCTN6 Mus musculus dynactin 6 (Dctn6), mRNA.   1.287151 
DUSP1 Mus musculus dual specificity phosphatase 1 (Dusp1), mRNA.   1.287093 
ZFP36 Mus musculus zinc finger protein 36 (Zfp36), mRNA.   1.28126 
RHOB 




IGF2 Mus musculus insulin-like growth factor 2 (Igf2), mRNA.   1.274712 
THY1 Mus musculus thymus cell antigen 1, theta (Thy1), mRNA.   1.271593 
MGAT3 




APRT Mus musculus adenine phosphoribosyl transferase, mRNA   1.26981 
SH3KBP1 





Mus musculus serine (or cysteine) peptidase inhibitor, clade A, 
member 3G (Serpina3g), mRNA. 
  
1.263668 
IRF1 Mus musculus interferon regulatory factor 1 (Irf1), mRNA.   1.262768 
PALM Mus musculus paralemmin (Palm), mRNA.   1.261623 
IGF1 
Mus musculus insulin-like growth factor 1 (Igf1), transcript 




Mus musculus HIV-1 Rev binding protein-like (Hrbl), transcript 








PLK2 Mus musculus polo-like kinase 2 (Drosophila) (Plk2), mRNA.   1.250674 
HIC1 
Mus musculus hypermethylated in cancer 1 (Hic1), transcript 



















     
ZCCHC3 










Mus musculus baculoviral IAP repeat-containing 5 (Birc5), 









Mus musculus protein phosphatase 1, regulatory (inhibitor) 
subunit 13B (Ppp1r13b), mRNA. 
  
1.244152 
H19 Mus musculus H19 fetal liver mRNA (H19) on chromosome 7.   1.241052 
TOP2A Mus musculus topoisomerase (DNA) II alpha (Top2a), mRNA.   1.237934 
NDST1 
Mus musculus N-deacetylase/N-sulfotransferase (heparan 




Mus musculus SET domain containing (lysine 













DUSP6 Mus musculus dual specificity phosphatase 6 (Dusp6), mRNA.   1.229589 
TNFRSF11B 
Mus musculus tumor necrosis factor receptor superfamily, 








RPIA Mus musculus ribose 5-phosphate isomerase A (Rpia), mRNA.   1.225795 
LSM3 
Mus musculus LSM3 homolog, U6 small nuclear RNA 
associated (S. cerevisiae) (Lsm3), mRNA. 
  
1.223725 
BMP3 Mus musculus bone morphogenetic protein 3 (Bmp3), mRNA.   1.222016 
FGF5 Mus musculus fibroblast growth factor 5 (Fgf5), mRNA.   1.221948 
TMEM8 
Mus musculus transmembrane protein 8 (five membrane-













     
HMGA1 
Mus musculus high mobility group AT-hook 1 (Hmga1), 








BBX Mus musculus bobby sox homolog (Drosophila) (Bbx), mRNA.   1.215977 
CHI3L1 Mus musculus chitinase 3-like 1 (Chi3l1), mRNA.   1.215013 
MTHFD1 
Mus musculus methylenetetrahydrofolate dehydrogenase 
(NADP+ dependent), methenyltetrahydrofolate cyclohydrolase, 
formyltetrahydrofolate synthase (Mthfd1), mRNA. 
  
1.213704 
E2F1 Mus musculus E2F transcription factor 1 (E2f1), mRNA.   1.212262 
BANF1 
Mus musculus barrier to autointegration factor 1 (Banf1), 









Mus musculus golgi membrane protein 1 (Golm1), transcript 
variant 2, mRNA. 
  
1.208051 
AXUD1 Mus musculus AXIN1 up-regulated 1 (Axud1), mRNA.   1.205341 
LIF 









FKBP1A Mus musculus FK506 binding protein 1a (Fkbp1a), mRNA.   1.204717 
ISG20L2 










Mus musculus basic helix-loop-helix domain containing, class 
























     
mRNA. 
PEAR1 
Mus musculus platelet endothelial aggregation receptor 1 
(Pear1), transcript variant 1, mRNA. 
  
1.200346 
     
SFRP2 









PDLIM3 Mus musculus PDZ and LIM domain 3 (Pdlim3), mRNA.   -1.46603 
ALDOC Mus musculus aldolase 3, C isoform (Aldoc), mRNA.   -1.45095 
SGK1 




INSIG1 Mus musculus insulin induced gene 1 (Insig1), mRNA.   -1.41735 
UNC45B 














PRPH Mus musculus peripherin (Prph), mRNA.   -1.36395 
FLRT2 




THBD Mus musculus thrombomodulin (Thbd), mRNA.   -1.34709 
PTGS1 





Mus musculus a disintegrin-like and metallopeptidase 




JAM2 Mus musculus junction adhesion molecule 2 (Jam2), mRNA.   -1.32023 
OGN Mus musculus osteoglycin (Ogn), mRNA.   -1.31751 
SEPP1 
Mus musculus selenoprotein P, plasma, 1 (Sepp1), transcript 













     
TAF9 
Mus musculus TAF9 RNA polymerase II, TATA box binding 




KRT14 Mus musculus keratin 14 (Krt14), mRNA.   -1.3036 
GNB2L1 
Mus musculus guanine nucleotide binding protein (G protein), 
beta polypeptide 2 like 1 (Gnb2l1), mRNA. 
  
-1.29407 
MMP11 Mus musculus matrix metallopeptidase 11 (Mmp11), mRNA.   -1.29144 
CALCA 
Mus musculus calcitonin/calcitonin-related polypeptide, alpha 




Mus musculus sema domain, immunoglobulin domain (Ig), short 








SNX1 Mus musculus sorting nexin 1 (Snx1), mRNA.   -1.28272 
MYH8 
Mus musculus myosin, heavy polypeptide 8, skeletal muscle, 
perinatal (Myh8), mRNA. 
  
-1.28221 
GPC2 Mus musculus glypican 2 (cerebroglycan) (Gpc2), mRNA.   -1.28021 
MCCC1 
Mus musculus methylcrotonoyl-Coenzyme A carboxylase 1 




Mus musculus phosphodiesterase 4D interacting protein 




Mus musculus pleckstrin homology domain containing, family 




GRTP1 Mus musculus GH regulated TBC protein 1 (Grtp1), mRNA.   -1.26576 
OXR1 Mus musculus oxidation resistance 1 (Oxr1), mRNA.   -1.26367 
XDH Mus musculus xanthine dehydrogenase (Xdh), mRNA.   -1.26142 
NNMT 




SEPT7 Mus musculus septin 7 (Sept7), mRNA.   -1.26024 
TUBB2B Mus musculus tubulin, beta 2b (Tubb2b), mRNA.   -1.25523 











     
polypeptide A6A (Ugt1a6a), mRNA. 
CXCL12 
Mus musculus chemokine (C-X-C motif) ligand 12 (Cxcl12), 




Mus musculus solute carrier family 10 (sodium/bile acid 
cotransporter family), member 6 (Slc10a6), mRNA. 
  
-1.25141 
JMJD3 Mus musculus jumonji domain containing 3 (Jmjd3), mRNA.   -1.24772 
CAV1 Mus musculus caveolin, caveolae protein 1 (Cav1), mRNA.   -1.24421 
AVPR1A 










Mus musculus nuclear factor of kappa light polypeptide gene 
enhancer in B-cells inhibitor, zeta (Nfkbiz), mRNA. 
  
-1.24031 
LPL Mus musculus lipoprotein lipase (Lpl), mRNA.   -1.24002 
ANTXR1 Mus musculus anthrax toxin receptor 1 (Antxr1), mRNA.   -1.23771 
COL3A1 Mus musculus collagen, type III, alpha 1 (Col3a1), mRNA.   -1.23603 
DDAH2 



















ANGPTL7 Mus musculus angiopoietin-like 7 (Angptl7), mRNA.   -1.23115 
IFI204 Mus musculus interferon activated gene 204 (Ifi204), mRNA.   -1.22856 
GDPD2 
Mus musculus glycerophosphodiester phosphodiesterase domain 









Mus musculus sema domain, immunoglobulin domain (Ig), short 













     
DHRS7 
Mus musculus dehydrogenase/reductase (SDR family) member 




Mus musculus acid phosphatase, prostate (Acpp), transcript 




Mus musculus sel-1 suppressor of lin-12-like (C. elegans) 













MMP13 Mus musculus matrix metallopeptidase 13 (Mmp13), mRNA.   -1.21802 
SYTL2 




PON3 Mus musculus paraoxonase 3 (Pon3), mRNA.   -1.2172 
PDGFRA 
Mus musculus platelet derived growth factor receptor, alpha 








PALMD Mus musculus palmdelphin, mRNA   -1.2153 
NAMPT 




KRBA1 Mus musculus KRAB-A domain containing 1 (Krba1), mRNA.   -1.21488 
IGFBP2 





Mus musculus ATG2 autophagy related 2 homolog A (S. 
cerevisiae) (Atg2a), mRNA. 
  
-1.21226 
NRG1 Mus musculus neuregulin 1 (Nrg1), mRNA.   -1.21063 
RGS10 




SULF1 Mus musculus sulfatase 1 (Sulf1), mRNA.   -1.20658 
CACNA1G 
Mus musculus calcium channel, voltage-dependent, T type, 













     
RAET1B 




ARRDC3 Mus musculus arrestin domain containing 3, mRNA   -1.20489 
CLK4 Mus musculus CDC like kinase 4 (Clk4), mRNA.   -1.20106 










 Pancreatic ductal adenocarcinoma (PDA) is a highly aggressive disease that 
takes the lives of the vast majority of affected patients.  Our knowledge of the 
molecular events underlying the development and progression of PDA has steadily 
increased, but this has not translated into more effective therapeutic approaches for 
treatment of the disease.  The work described in this thesis has taken a focused 
approach at trying to better characterize the pancreatic tumor microenvironment.  A 
detailed understanding of the cross-talk between tumor and stromal cells may hold 
clues to affectively targeting pancreatic tumors in new ways.  We have identified that 
Hedgehog (Hh) signaling is one of the important feedback mechanisms between 
pancreatic tumor cells and the infiltrating stroma.  Targeting paracrine Hh signaling 
in the tumor stroma can have significant effects on tumor biology, including 
reduction in metastatic spread, changes in tumor cell differentiation, decreases in 
tumor desmoplasia, and disruption of the cancer stem cell population.  Future studies 
will be aimed at understanding how paracrine Hh signaling and downstream Hh-
target genes affect the biological function of the tumor mesenchyme and of the tumor 






The Hedgehog pathway is widely studied for its role in the regulation of 
growth, development and maintenance of many different tissues within the organism.  
While this pathway has a clear, canonical mechanism for autocrine and paracrine 
signaling in normal tissues, this is not the case for pancreatic tumor cells [33].  The 
experiments described in this thesis confirmed a role for paracrine Hh signaling in the 
pancreatic tumor microenvironment.  Our studies have also shown an important role 
of Hh signaling in mediating the invasiveness of the tumor along with maintaining the 
differentiation of the tumor cells which has not been previously described.  
Additionally, this thesis details the first transcriptional profiling analysis of Hh 
responsive genes in pancreatic stellate cells. Bioinformatics analysis of differentially 
expressed genes proposed several ways in which the Hh pathway may impact the 
pancreatic tumor microenvironment.  One of these functional roles was related to 
enhancing the motility of pancreatic stellate cells in three-dimensional extracellular 
matrix, which was validated using an in vitro model system.  The functional studies 
and model systems that are described in this thesis provide the framework for asking 
important questions about the role of paracrine Hh signaling in pancreatic cancer.  
 
Role of Paracrine Hh signaling in vivo 
In Chapter 2, we examined the effect of Hh pathway antagonist, HhAntag, 
alone or in combination with gemcitabine in an orthotopic model of human pancreatic 
ductal adenocarcinoma (PDA).  Essentially all drugs that are approved for anti-cancer 
therapy have been tested using a subcutaneous xenograft model in immune-deficient 
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mice and showed promising activity before being evaluated in early clinical trials.  
Unfortunately, these successes have often been met by failures in a clinical trial 
setting, including trials for: antagonists of the human epidermal growth factor 
receptor (EGFR) pathway, vascular endothelial growth factor (VEGF) pathway, 
insulin-like growth factor (IGF) pathway, and phosphoinositide 3’-kinase 
(PI3k)/Akt/mammalian target of rapamycin (mTOR) signaling [27,28,118,119].  In a 
retrospective study performed by the National Cancer Institute (NCI), only one-third 
of all tested human xenograft studies had some activity in Phase II clinical trials, but 
even this was highly variable depending on the particular tumor histology [146].  
Activity in breast cancer xenografts predicted poorly, whereas lung cancers, 
particularly adenocarcinomas, tend to respond better in comparison to the other 
diseases.  
Why are subcutaneous xenograft models systems so poor at predicting 
therapeutic activity in the clinic?  One reason may be that these pre-clinical studies 
often use xenografts established from immortalized cancer cell lines.  These 
individual lines have often been established decades prior to use in pre-clinical 
models and after years of in vitro culture and selection, these cells likely do not retain 
the same genetic background or phenotypic characteristics as the original tumor from 
which the cell line was derived [147].  Our personal observation in deriving 
xenografts from patients with pancreatic adenocarcinoma is that there is a diverse 
phenotype in primary patient tumors that does not correlate with xenograft tumors 
from pancreatic cancer cell lines.  These differences range from the amount of 
desmoplasia that the tumor develops, varying degrees of tumor histolopathology 
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which range from highly undifferentiated to mucionous neoplasms, along with 
differing levels of expression of important signaling ligands such as Sonic hedgehog 
(Chapter 2, Figure 2.1).  Validating these observations are pre-clinical studies done 
from a large panel of xenografts derived from patient biopsies, instead of cancer cell 
lines, and activity in these xenografts was compared with clinical response. A strong 
prediction of clinical outcome was observed for both tumor resistance (97%) and 
tumor sensitivity (90%) in these studies [148]. 
In line with using individual patient xenografts for establishing pre-clinical 
models, our lab has established over 30 primary xenografts from patients with 
pancreatic adenocarcinoma.  We utilized 13 of these tumors in our study and 
compared the pathology and gene expression profile of Hh signaling ligands and 
downstream target genes (Chapter 2, Table 2.2).  As might be expected, we 
identified a range of expression of Sonic and Indian hedgehog ligands in these 
tumors, and the expression of these factors correlated with the expression of Hh target 
genes, Gli1 and Patched1, in the mouse stroma.  Ectopic expression of Sonic 
hedgehog in a transformed, ductal-derived pancreatic epithelial cell line has 
correlated with a strong desmoplastic reaction that is reversible with inhibitors of the 
pathway [81].  An observation that we note is that two patient xenografts with the 
highest levels of Shh and Ihh expression also have the highest amount of infiltrating 
mouse stroma of the tumors that we examined in this study (Figure 4.1).  Recent 
studies in transgenic animal models of pancreatic cancer have shown that the high 
level of desmoplastic stroma corresponds to tumors with a disorganized vasculature 
which limits the ability of chemotherapeutic drugs to reach their target within the 
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tumor [80,125].  This warrants expansion of our study to more patient xenografts to 
determine if there is a correlation with Hh ligand expression, tumor pathology and 
patient survival.  This might aid in identifying patient groups which would benefit 
most from inhibition of paracrine Hh signaling.    
Subcutaneous xenograft models of pancreatic cancer are not ideal due to their 
rare metastatic potential and reduced propensity to display highly invasive 
phenotypes.  These properties are important as 85% of patients present clinically with 
advanced, inoperable disease [21].  For our studies, we established an orthotopic 
model of pancreatic adenocarcinoma by implanting tumor cells that were dissociated 
from individual patient xenografts (one that was spontaneously metastatic), directly in 
the distal pancreas of NOD/SCID mice.  The advantage of this approach is that it 
allowed us to test the effect of inhibition of paracrine Hh signaling with or without 
co-treatment with gemcitabine on the progression of tumors with the genetic and 
histological profiles that reflected the in vivo characteristic found in the patient.  
These tumor cells were “tagged” by transducing them with a lentiviral construct that 
expresses Renilla-luciferase, and allowed us to perform non-invasive imaging of the 
animals to establish baseline tumor sizes prior to beginning therapy and monitor 
progression of the tumor growth during treatment (Figure 4.2) [149].  We believe 
that this is the first description of this platform using pancreatic adenocarcinoma cells 
derived from individual patients and provides a unique pre-clinical model for testing 
potential therapies.     
To test how inhibition of paracrine Hh signaling affected the progression of 
pancreatic tumor growth in our system, we compared the treatment of two patient 
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xenografts with an inhibitor of the Hh pathway, HhAntag, and gemcitabine, the drug 
most commonly given to pancreatic cancer patients.  HhAntag is a compound that 
was developed by Genentech that is 10 times more potent than the natural, 
Smoothened antagonist of the pathway, cyclopamine, and has been used in animal 
models to down-regulate Hh signaling in a wide range of malignancies [33,150].  
Both PDA xenografts treated with HhAntag alone did not demonstrate a significant 
reduction in primary tumor size from vehicle treated animals.  This is somewhat 
contrary to a previous report showing that blocking paracrine Hh signaling with 
HhAntag in a subcutaneous xenograft of pancreatic cancer led to a delay in tumor 
growth [33].  However, this study used a single pancreatic tumor implanted 
subcutaneously, which did not metastasize and the amount of desmoplasia was 
undocumented.  These discrepancies highlight the need to expand treatment studies to 
a large range of tumors to be able to draw better conclusions on the effect of Hh 
pathway inhibition on a wide range of patient tumors.  Additionally, in the analysis of 
the expression of Hh ligands expressed in the PDA tumors in our study we observed a 
wide range of Shh and Ihh expression in tumors.  The xenografts chosen for our study 
expressed Shh and Ihh at levels slightly below the statistical median for the tumors 
that we analyzed.  It is possible the HhAntag may be more affective at slowing the 
growth of pancreatic tumors with a higher level of paracrine Hh activation.  Our 
results would suggest that testing a wide range of tumors with different Hh expression 
may help identify the phenotype of tumors which will respond best to inhibition of 
paracrine Hh signaling. 
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The orthotopic tumors in our studies responded significantly better to 
gemcitabine than the observed clinical response of patients in the clinic.  There is 
some debate as to whether the orthotopic transplantation into SCID mice used in our 
study are the best model for pancreatic cancer as these animals lack important 
components of the immune system which may limit the desmoplastic reaction 
[80,151].  Indeed, de novo pancreatic disease arising from transgenic expression of 
mutant KRAS and p53 alleles in the pancreas result in tumors that have a higher 
desmoplastic reaction and more deficient vascular network than xenotransplanted 
pancreatic tumor cells [80].  While we do observe a decreased amount of infiltrating 
stroma in our PDA xenografts compared to patient sections from the original tumor, 
this is variable from tumor to tumor and indeed may be dependent on the expression 
of signals, including Hh ligands, from the tumor cells.   
Interestingly, we have also observed evidence of decreased perfusion of 
tumors, and possibly chemotherapeutics in our orthotopic xenograft model.  We 
utilize non-invasive bioluminescent imaging (BLI) to monitor the progression of 
tumors during treatment.  Several times near the end of the 21 day treatment protocol, 
we encountered the complete loss of signal from a tumor that had a clear BLI signal 
the previous week, primarily in those animals treated with vehicle or HhAntag.  The 
mechanism for this imaging is via intraperitoneal (IP) injection of luciferin, an 
oxidizable substrate that travels through the bloodstream and upon encountering the 
luciferase enzyme (expressed by our “tagged” tumor cells) releases a bioluminescent 
signal detected by a sensitive charge-couple device (CCD) camera [152].  When we 
recovered tumors from the animals that showed a loss of BLI signal and tested them 
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in culture with luciferin, these cells demonstrated competent BLI activity suggesting 
that the construct was not silenced.  We believe this suggests that there is a point 
during the growth of the orthotopic xenograft tumors where there is a reduction in 
vascular integrity.  Supportive of this contention is the observed increase in necrosis 
in the center of tumors, especially those recovered from animals that were treated 
with vehicle or HhAntag alone.  It is possible that the continued sensitivity to 
gemcitabine treatment in our model is more about timing of the treatment: we are 
treating the animals during a time period where the tumor is highly vascularized and 
permits diffusion of compounds to the tumor.  Studies are on-going to see if we can 
accelerate the process of desmoplasia by co-implanting tumor cells along with tumor 
associated fibroblasts.  This may help us achieve a more clinically accurate tumor 
model in which the xenografts are less sensitive to gemcitabine.   
Despite the limitations described above, we believe that our model is relevant 
to investigation of the interactions between tumor cells and the stroma.  The 
orthotopic tumors in our model system develop a desmoplastic reaction and we have 
identified several patient xenografts which form spontaneous metastases that have 
only been seen in specially selected pancreatic cell line xenografts [153].  
Additionally, transgenic animal models of pancreatic cancer generate a single genetic 
and histopathological profile of the disease, while use of primary PDA xenografts 
allows us access to test therapies against tumors with varying grades of 
differentiation, genetic background and stromal involvement which represents the 
true patient population.      
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The most striking result from our in vivo experiments was the marked 
inhibition of metastases in xenograft UM-PDA#1 with HhAntag treatment alone or in 
combination with gemcitabine while the primary tumor showed only a marginal 
decrease in size.  These experiments show the vital dependence of the pancreatic 
tumor cells with its mesenchyme in the tumor microenvironment.  A recent study 
using an organotypic assay of tumor cell invasion demonstrated how mesenchymal 
cells at the leading edge of the tumor carve tracks through the extracellular matrix, 
which the tumor cells then use to invade into surrounding tissues [145].  Additionally, 
presence of stromal cells in a three-dimensional model of pancreatic tumor cell 
invasion leads to an epithelial-to-mesenchymal transition with significant decreases in 
E-cadherin expression and an increase in β-catenin signaling resulting in the 
increased invasion of the tumor cells [154].  These studies highlight the potential 
importance of modulating the tumor stroma in prevention or possible treatment of 
metastatic disease.   
 While we are not exactly sure how blockage of paracrine Hh signaling in the 
stroma results in the reduction in metastatic spread, we have some clues from our 
experiments and from similar studies in the literature.  The negative effect of 
HhAntag treatment on the metastatic seeding of pancreatic adenocarcinoma cells 
suggests that HhAntag does one or several things to the tumor mesenchyme.  It may 
reduce the expression of factors in the stroma that promote the functional ability of 
cancer cells to invade.  For example, tumor cells and mesenchymal cells are 
dependent on an MT1-MMP mechanism for degradation of basement membrane and 
invasion in type I collagen matrix [155,156].  It is possible that HhAntag treatment 
 107 
disrupts signals in mesenchymal cells that localize MT1-MMP to the membrane, and 
this leads to a reduction in cell motility.  Additionally, some of the same motility 
factors, including MMP-2, MT1-MMP, and TIMP-2 are involved in the extravasation 
of tumor cells from the bloodstream so it is possible that some tumor cells may be 
able to leave the tumor but cannot engraft in a new site [157].  Importantly, we find 
that Hh treatment of pancreas-derived fibroblasts up-regulate motility and 
angiogenesis pathways, indicating a mechanism that could be important for metastatic 
disease.  Another possibility is that tumor-derived Shh is required to produce 
desmoplastic stroma at the site of metastasis and by blocking this with Hh inhibitors it 
prevents the establishment of these distant lesions. 
Treatment with HhAntag alone and in combination with gemcitabine also 
revealed distinct changes in the tumor histological profile, with an apparent increase 
in differentiation of tumor cells and expression of mucins.  The change observed in 
tumor histology with Hh inhibition has not been previously reported.  Mucins 
comprise a large family of glycoproteins that are secreted or bound to the cellular 
membrane and either directly or indirectly, act to maintain the integrity of the cellular 
membrane, along with lubricating and protecting the epithelial surfaces in animal 
tissues [158].   In our studies, we observed a significant up-regulation of MUC2, a 
secreted mucin, with HhAntag plus gemcitabine treated tumors (not shown).  It is 
unclear whether the change in histology alters the invasiveness of pancreatic cancer 
cells or simply reflects a less aggressive phenotype, but a clinical study of MUC2 
expression across a panel of pancreatic adenocarcinoma tumors revealed a better 
prognosis with higher MUC2 expression [159].     
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Another hypothesis for the reduced metastatic potential of tumors following 
HhAntag is that the drug treatment disrupts factors that maintain the minor population 
of cells which are capable of new tumor initiation.  However, in the case of UM-







 cells (greater than 40%) that we have analyzed and neither 
HhAntag or gemcitabine treatment affected the level of this cell population compared 
to vehicle treated animals.  In contrast, we did observe significant reductions in 
markers related to the tumorigenic population of cells in UM-PDA#2 and this 
corresponded with delayed growth following re-implantation, but this xenograft 
tumor did not show evidence of metastases in vivo.  A similar study using the Smo-
inhibitor, IPI-269609 (Infinity Pharmaceuticals) to treat pancreatic cell line 
xenografts noted a reduction of Aldefluor positive (ALDH
+
) cells, an activity assay 
for aldehyde dehydrogenase used to profile cancer stem cells in several malignancies 
[102,103,122].  Some preliminary experiments suggest that ALDH
+
 cells were 
reduced in our HhAntag treatment groups in UM-PDA#1 xenografts (not shown).  It 
is possible that our current markers are not as accurate at marking the true tumor 
initiating population and current studies in our laboratory suggest that a more accurate 
stem cell marker includes c-Met, also known as the hepatocyte growth factor receptor 
(HGFR).  MET/HGFR is a receptor tyrosine kinase that binds hepatocyte growth 
factor (HGF) and has been implicated in cell survival and invasiveness in pancreatic 
cancer [160].  FACS analysis of tumor cells from HhAntag treatment groups with c-
Met may reveal more accurate changes in the tumor-initiating cell population.      
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Pancreatic adenocarcinoma has a multi-decade long history of failed efforts in 
identifying an effective chemotherapeutic treatment regimen.  The latest failed efforts 
included the use of use epidermal growth factor receptor (EGFR) inhibitors (Erbitux) 
in combination with radiation and treatments with vascular endothelial growth factor 
receptor (VEGFR) inhibitor, bevacizumab (Avastin).  None showed significant 
effects in patient outcomes [27,161].  Gemcitabine, the currently accepted regimen 
for pancreatic cancer, only affords patients an average of a few weeks of increased 
survival [151].  These failures are likely due in part to the unique biology of the 
pancreatic tumor microenvironment.  Pancreatic tumors are very fibrotic and recent 
studies suggest that these tumors have a disorganized vasculature which does not 
allow robust tumor perfusion [80].  Any therapy which may help to control the 
desmoplasia of the tumor could significantly impact the ability of chemotherapeutic 
agents or other secondary therapies to reach the tumor.  It is clear from our studies 
that use of Hh antagonists in pancreatic tumors can affect the tumor mesenchyme and 
these effects are materialized in the inability of the tumor from invading into the local 
organ environment and altering the native differentiation of the epithelial cells.  These 
are exciting results that will help us better understand how to use Hh pathway 
inhibition in combination with secondary agents to affect patient outcomes. 
 
Functional Changes Induced by Hh signaling in Pancreatic Stellate Cells 
In Chapter 3, we have provided the first documented transcriptional analysis 
of pancreatic stellate cells following Sonic Hedgehog stimulation.  Our previous 
studies in Chapter 2 had demonstrated how pancreatic tumor cells activate Hh 
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signaling in the tumor mesenchyme by secretion of Hh pathway ligands but it was not 
clear which gene pathways were modulated by Hh signaling.  The importance of 
these pathways were validated by targeted inhibition of paracrine Hh signaling in vivo 
that led to reduced tumor spread.  The Hh pathway is well characterized for its role as 
a morphogen in developing epithelial tissues [162].  There is less information as to 
how activation of this pathway affects the mesenchyme and mediates cross-talk 
between epithelial and mesenchymal interactions.  In the intestinal epithelium, Hh 
signaling mediates anti-inflammatory signals with the local mesenchyme. Inhibition 
of Hh signaling can lead to intestinal inflammation and death in animal models [82].   
In pancreatic development, ectopic expression of Sonic hedgehog under the control of 
the Pdx-1 promoter in the developing epithelial anlage is incompatible with pancreas 
organogenesis with loss of both exocrine and endocrine tissue [58]. The pancreatic 
mesenchyme itself is transformed into duodenal mesoderm with functional layers of 
muscle that possess the ability to constrict, demonstrating that epithelial-derived Shh 
can impart important biological changes in the local mesenchyme.  Recent studies of 
specialized pancreatic duct glands (PDGs) in the adult organ have been shown to 
express Shh in response to injury and may induce Hh-related factors in the stroma 
that mediate the transition of epithelial duct cells to a mucinous, metaplastic 
phenotype [163]. 
The pancreatic tumor microenvironment is dominated by infiltrating stroma 
and desmoplasia that surround the tumor cells.  A major cause is the activation of 
pancreatic stellate cells (PSCs), which are specialized pancreatic fibroblast cells 
located at the periphery of the acini in the exocrine pancreas and are normally 
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quiescent [129].  Activation of PSCs can be mediated by growth factors and 
cytokines, such as TGF-β1, or oxidant stress which results in their transformation 
from a quiescent to a myofibroblast-like phenotype, which secretes excess amounts of 
extracellular matrix components [139].  To characterize the role of Hh signaling in 
these cells, we developed two cell lines to use for in vitro experiments.  Initial 
attempts at culturing normal fibroblasts from human or mouse pancreas revealed that 
these cells often senesce in culture after only a few passages.  We changed our 
strategy to culture pancreatic fibroblasts from mice induced with chronic pancreatitis, 
as correspondence with our collaborators suggested that fibroblasts from these mice 
have a higher proliferative capacity in vitro.  We utilized this strategy in 
Immortomouse animals, which allowed us to develop a primary, conditionally 
immortalized cell line [131].  The development of these tools allowed us to ask 
important questions about the consequences of Hh signaling in pancreatic stellate 
cells.   
Several previous studies have been performed to identify the Hh-related genes 
in mesenchymal cells, including embryonic fibroblasts and organ specific 
mesenchyme in the intestine and prostate [82,83,164].  Profiling studies of tumor-
stromal interaction of prostate mesenchyme revealed that Shh-stimulation altered the 
transcriptional response of adult prostate mesenchyme to mimic the growth 
promoting actions of the fetal mesenchyme [165].  Studies analyzing the 
transcriptional profile of Shh and Ihh stimulated intestinal mesenchyme revealed a 
previous unknown function of Hh signaling in mediating anti-inflammatory signals in 
the tissue [82].  We performed transcriptional profiling of Shh-stimulated pancreatic 
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stellate cells and meta-analysis with prostate and intestinal Hh-related gene sets to 
learn what genes and pathways are consistent with Hh activation in mesenchymal 
cells and what genes may be specific to the pancreatic tumor microenvironment.  Not 
surprisingly, we identified several genes that have been identified as Hh-related genes 
in Gdf10, Nkx2-3, Ang-4, Hes1, Sfrp-2, IGF1 and IGF2.  Additionally, we identified 
some factors that had not been shown to be Hh-related genes in Wnt2, TGFβ2, R-
spondin1, and Fgf9.  We propose that these target genes may have roles in regulating 
the angiogenic-function of pancreatic stellate cells along with mediation of epithelial-
to-mesenchymal transition and increased invasion of pancreatic tumor cells.   
A recent study of Hh-responsive bone marrow-derived mesenchymal cells 
demonstrated the reliance of paracrine Hh signaling in regulating the expression of 
Ang-1 and IGF-1, which promoted the neovascularization of the tumor [86].  In our 
data set we observed the up-regulation of VEGFA, which has been shown to be the 
predominant vascular endothelial growth factor related protein in pancreatic tumor 
epithelial cells and likely plays an important role in mediating the neo-vascularization 
of the tumor [166].  While VEGF inhibitors have not provided significant clinical 
benefit to pancreatic cancer patients, this result may have more to do with drug 
delivery to the effective area in the tumor rather than the dependence of the tumor on 
these factors for tumor growth and development [27].  Alternatively, the tumors may 
have adapted to a relatively oxygen poor environment, rendering the reduction in 
vascularity by VEGF relatively ineffective.  Interestingly, while we observed a 
number of angiogenic-related factors that were increased in pancreatic stellate cells 
following Shh-stimulation, study of a transgenic mouse model of pancreatic cancer 
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showed an increase in the vasculature following treatment of the animals with an Hh 
pathway inhibitor [80].  This seems counter-intuitive to successful treatment of 
pancreatic cancer, but the authors suggest that the more organized vascular network 
allows better penetrance of chemotherapeutic compounds.  Closer study of 
angiogenesis-related genes following paracrine Hh inhibition in vivo may provide 
more answers into how these factors are manipulated by Hh signaling in the tumor 
microenvironment. 
A striking result in our studies in Chapter 2 was the abrogation of metastases 
in animals treated with HhAntag alone or in combination with gemcitabine.  We 
hypothesized that transcriptional profiling of Hh target genes in pancreatic stellate 
cells might provide us clues into how this pathway mediates the invasiveness of 
tumor cells.  Interestingly, we noted a number of Wnt pathway related genes in our 
data set including increases in Wnt2 and R-spondin-1, and the single most down-
regulated gene in our data set was Sfrp-2, an important inhibitor of Wnt pathway 
signaling [167].  Additional studies have shown that the pro-invasive activity of Wnt2 
may go through a non-canonical mechanism involving GSK-3β and c-Jun/AP-1 
signaling [168].   Canonical Wnt signaling has been shown to be active in pancreatic 
adenocarcinoma cells [140].  While there is a report of Wnt5a up-regulation and Sfrp-
1 down-regulation in the pancreatic tumor stroma [141], to date there is not a clear 
mechanism of how Wnt pathway affects the biological function of pancreatic tumor 
mesenchyme.  Recent studies have suggested a role for Wnt to enhance proliferation 
in the epithelium and stroma of chemically induced bladder cancer in mice [142].  In 
this work, Shh expression in basal cells of the bladder increases upon injury and 
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elicits increased stromal expression of Wnt protein signals, which in turn stimulate 
the proliferation of both urothelial and stromal cells.  This type of feedback 
mechanism may also be at work in the pancreatic tumor microenvironment.  
Preliminary data examining the differential expression of Wnt ligands in Shh-
stimulated pancreatic stellate cells revealed that only Wnt2, Wnt5b, and Wnt3a were 
significantly changed (Figure 4.3).  We have also targeted the knock-down of Wnt2 
in PSCs and this appears to block the ability of the cells to migrate in response to 
sonic hedgehog (Figure 4.4).  Future studies will be aimed at identifying how 
Hedgehog/Wnt feedback may play an important role in mediating the growth and 
invasion of pancreatic tumor cells.    
 
Clinical Efficacy of Paracrine Hh Inhibition in Treating Pancreatic Cancer 
 While we have demonstrated some exciting results in targeting paracrine Hh 
signaling in xenograft models of pancreatic cancer, we realize that success in animal 
models have rarely translated to success in the clinic.  To date, the only hope for a 
cure from pancreatic cancer is surgical resection of the disease; however, roughly 
85% of patients diagnosed with pancreatic adenocarcinoma are presented with an 
inoperable diagnosis.  That makes identifying therapies that are effective at reducing 
tumor growth that convert a patient into a surgical candidate, or finding therapies that 
help to prevent the recurrence of pancreatic disease crucial.  
 Recently, a phase I clinical trial (UMCC 2010.003) has been initiated at the 
University of Michigan Medical Center for the treatment of patients with metastatic 
pancreatic ductal adenocarcinoma with GDC-0449, a Smoothened antagonist and 
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potent Hh pathway inhibitor developed by Genentech.  The plan for this study is to 
include 25 patients with metastatic disease.  The primary endpoint is to assess the 
biological effects of Hh inhibition on cancer stem cells and Hh signaling with 
secondary endpoints examining clinical outcome parameters.  All patients in this trial 
will have core biopsies taken before treatment with GDC-0449 to establish a baseline 
of Hh pathway activity.  Patients will then undergo a first cycle of GDC-0449 
monotherapy for two weeks, following which another core biopsy will be taken to 
assess Hh-regulated changes in the tumor.  Cycle 2 will then administer Gemcitabine 
infusion 3 times a week for 28 days.  CT scans will be used to assess response at 8 
week intervals. 
 Preliminary results of this trial have demonstrated some exiting results and 
important correlations with our xenograft study.  Five patients have been evaluated 
for a response to GDC-0449 pre-treatment followed by gemcitabine treatment and 
have confirmed a partial response in 3 out of 5 patients.  CT scans of patients 
following GDC-0449 treatment alone revealed very little change in the amount and 
size of metastases, which correlates with our xenograft study that demonstrated very 
little change in tumor volume with HhAntag treatment.  However, following a 
treatment cycle with both gemcitabine and GDC-0449 a significant reduction in the 
metastatic liver lesions of several patients was observed (Figure 4.5 A).  In addition, 
a reduction in CA-19-9 levels, a serum marker used diagnostically in pancreatic 
cancer, following the GDC-0449 and gemcitabine treatment cycle (Figure 4.5 B) has 
been observed.  Additionally, histological changes with increased vacuolated 
structures in tumor cells of one patient following GDC-0449 treatment, consistent 
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with our findings following treatment of orthotopic tumors in mice with HhAntag 
(Chapter 2, Figure 2.6). 
 While this clinical trial is still in the early stages, the results are encouraging 
that targeting paracrine Hh signaling in pancreatic cancer patients may be a viable 
therapeutic strategy.  As treatment has resulted in variable response in patients, it will 
be important to identify what parameters correlate with success, whether that may be 
levels of Hh ligands, expression of cancer stem cell markers, or the expression of 
certain Hh target genes in the tumor stroma.  In the future, we hope to test inhibition 
of Hh signaling in a model of established liver metastases.  This model may help us 
understand how Hh signaling of tumor cells in metastatic sites affects other organ 
microenvironments.  
 
Proposed Model of Hh Signaling in Pancreatic Cancer 
 Based on the studies presented in this thesis, we propose an updated model for 
how paracrine Hh signaling in the tumor microenvironment plays critical roles in the 
epithelial to mesenchymal cross-talk of the tumor (Figure 4.6).  We believe that in 
early neoplasms of the pancreas, where Sonic hedgehog has been shown to be 
expressed [30], activation of Hh signaling acts as a activator and mitogen, increasing 
the proliferation of pancreatic stellate cells and enhancing the desmoplastic reaction 
and possibly attracting bone marrow derived pro-angiogenic cells to the tumor site 
[86].  As the tumor progresses to more advanced stages, Hh pathway activation in 
stellate cells stimulates the release of factors that allow the tumor to invade into the 
vascular and lymphatic system.  These factors are likely related to VEGFA, IGF, and 
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TGFβ pathways along with increased expression of ECM remodeling proteins 
defined in our gene profiling experiments.  Additionally, Hh signaling in the 
mesenchyme causes the expression of factors that maintain the differentiation status 
of the tumor, which we proposed is mediated by Wnt pathway signals from the tumor 
mesenchyme.   
In all, this thesis details experiments which have increased our understanding 
for the role of Hh pathway signaling in the pancreatic tumor microenvironment.  
Future work will aim to answer additional important questions about the key factors 
that are involved in the different aspects of pancreatic tumor biology.  We hope that 
these studies will provide important clues in how we can use Hh pathway inhibition 
to provide better therapeutic options for pancreatic cancer patients. 
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FIGURES 
Figure 4.1 Histological Comparison of Patient vs. Cell Line Xenografts. 
Representative sections from three individual patient xenografts and one xenograft 
generated from implantation of Panc-1 cells.  Upper left and right panels represent 
xenografts with the highest expression of Sonic hedgehog (Shh), while the bottom left 
shows a xenograft with comparatively low expression of Shh.  Notice the difference 
in tumor architecture and in the amount of infiltrating stroma.  Bottom right is a Panc-
1 pancreatic cancer cell line xenograft stained for sonic hedgehog.  Tumor cells are 
very compact with little or no gland formation.   
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Figure 4.2 Bioluminescent Imaging (BLI) of Pancreatic Ductal Adenocarcinoma.  
(A) Animals with luciferase “tagged” patient tumor cells implanted in the pancreas, 3 
weeks post-implantation  (B) Whole organ systems; bowel, lungs, kidneys, and spleen 
shown here, can be imaged individually to detect both macro- and micro-metastases 









Figure 4.3 Differential Expression of Wnt ligands in Shh-treated PSCs.  
Quantitative expression analysis (qRT-PCR) of Wnt pathway ligands following Shh-




































































































Figure 4.4 Knockdown of Wnt2 Decreases 2D Migration of Shh-stimulated 
PSCs.  (A) PSCs transfected with Wnt2 siRNAs decreases the amount of Wnt2 
transcript by 60% after 48hrs.  (B) PSCs with Wnt2 knockdown show a significant 
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Figure 4.5 Clinical Trial of GDC-0449 in Patients with Metastatic Pancreatic 
Cancer.  Above, CT scans from a patient pre and post treatment with GDC-0449 and 
gemcitabine.  Arrows denote liver metastases found prior to treatment.  Below, 
patient CA-19-9 serum levels (diagnostic measure of tumor burden) actually increases 
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Figure 4.6 Model for Paracrine Hh Signaling in the Pancreatic Tumor 
Microenvironment. (A) Paracrine activation of Hh signaling in the tumor 
mesenchyme activates stellate cell proliferation and deposition of collagen, 
fibronectin and other ECM components. (B) Activation of Hh-target genes in the 
tumor stroma creates a positive feedback loop with tumor cells.  These secreted 
factors may include Wnt, IGF and TGFβ proteins.  Neo-vascularization of the tumor 
may be aided by IGF-1 and Angiopoietins that may be secreted by the stromal cells in 
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